Ophthalmology – Steroid-Induced Glaucoma

What the Disorder Represents

Steroid-induced glaucoma is a secondary open-angle glaucoma caused by corticosteroid-related reduction in aqueous outflow through the trabecular meshwork.

The sequence is:

Corticosteroid exposure → increased trabecular outflow resistance → elevated IOP → glaucomatous optic nerve damage if sufficiently severe or prolonged

An important distinction is:

• Steroid-induced ocular hypertension = IOP elevation without glaucomatous damage
• Steroid-induced glaucoma = IOP elevation with characteristic optic neuropathy and/or visual-field loss

Which Steroids Can Cause It

Virtually any corticosteroid route can produce an IOP response, including:

• Topical ophthalmic drops
• Periocular injections
• Intravitreal injections
• Intravitreal steroid implants
• Systemic corticosteroids
• Inhaled corticosteroids
• Intranasal corticosteroids
• Dermatologic preparations, particularly when applied around the eyelids

Risk varies considerably according to:

• Steroid potency
• Dose
• Duration
• Route
• Individual susceptibility

Which Routes Carry the Greatest Ocular Risk

The largest and most prolonged IOP elevations are often seen with:

• Intravitreal corticosteroids
• Sustained-release intraocular steroid implants
• Periocular depot steroids

Topical ophthalmic steroids are also a common cause because they are frequently prescribed.

Systemic, inhaled, intranasal, and dermatologic formulations generally carry lower ocular risk but can still cause clinically important IOP elevation in susceptible patients.

What Is a Steroid Responder?

A steroid responder is a patient who develops a clinically meaningful rise in IOP after corticosteroid exposure.

Responses range from:

• Minimal
• Moderate
• Marked

A small proportion of the general population are:

High steroid responders

and may develop substantial IOP elevations even with relatively short treatment courses.

Who Is Most Susceptible

Risk is increased in patients with:

• Primary open-angle glaucoma
• Ocular hypertension
• First-degree family history of glaucoma
• Previous steroid-induced IOP elevation
• High baseline IOP
• High myopia
• Diabetes mellitus
• Young children
• Older adults

Patients with advanced pre-existing glaucoma are particularly vulnerable because even a moderate additional IOP rise may cause further damage.

Why Children Require Special Attention

Children can develop:

• Rapid
• Large
• Occasionally asymptomatic

IOP elevations after topical or systemic corticosteroids.

This is particularly important when steroids are prescribed for:

• Uveitis
• Vernal keratoconjunctivitis
• Postoperative inflammation
• Dermatologic disease around the eyes

IOP monitoring should not be omitted simply because the patient is young.

How Steroids Raise IOP

Corticosteroids act through glucocorticoid receptors in trabecular meshwork cells and produce several changes that reduce aqueous outflow.

These include:

• Increased extracellular matrix deposition
• Altered actin cytoskeleton
• Reduced trabecular meshwork phagocytosis
• Reduced degradation of extracellular material
• Altered cell-cell and cell-matrix adhesion
• Increased expression of proteins such as myocilin

The result is:

Higher resistance to aqueous passage through the conventional outflow pathway.

Relationship to Myocilin

Corticosteroids can increase:

MYOC/myocilin expression

in trabecular meshwork cells.

MYOC mutations are also associated with:

• Juvenile open-angle glaucoma
• Some adult-onset open-angle glaucoma

However, steroid-induced glaucoma itself is not simply a MYOC mutation disorder.

When IOP Usually Starts to Rise

With topical ophthalmic corticosteroids, IOP commonly begins to rise after approximately:

2–6 weeks

although elevation can occur:

• Within days in highly susceptible patients
• Much later during chronic treatment

Depot or sustained-release intraocular steroid preparations may cause elevation:

Weeks to months after administration

and the effect may persist for a prolonged period.

Why Timing Can Be Misleading

A patient may develop steroid-related IOP elevation even after:

• Months of apparently safe treatment
• Repeated previous steroid courses without difficulty

Therefore a normal early IOP does not eliminate later risk.

What Happens After Steroids Are Stopped

After discontinuing topical corticosteroids, IOP often returns toward baseline over:

Days to several weeks

However, normalization may take longer after:

• Long-term exposure
• Depot injections
• Intravitreal implants

Some patients with underlying glaucoma may continue to require treatment even after the steroid effect resolves.

Why Route and Molecule Matter

More potent ocular steroids generally have a greater tendency to raise IOP.

Higher-risk agents include:

• Dexamethasone
• Prednisolone acetate
• Difluprednate

Agents with a generally lower propensity for IOP elevation include:

• Loteprednol
• Fluorometholone

However:

No corticosteroid is completely free of steroid-response risk.

Why Loteprednol Is Often Chosen

Loteprednol is designed to undergo rapid metabolism after exerting its anti-inflammatory action.

This tends to produce:

A lower average risk of clinically significant IOP elevation

than stronger ketone corticosteroids such as prednisolone or dexamethasone.

It is still capable of raising IOP in susceptible patients.

What Patients Usually Notice

Most patients with steroid-induced ocular hypertension are:

Asymptomatic

even when IOP is significantly elevated.

When IOP becomes very high, symptoms may include:

• Ocular discomfort
• Headache
• Blurred vision
• Halos

But absence of symptoms provides:

No reassurance that the IOP is normal.

History That Should Always Be Taken

Ask specifically about every possible corticosteroid source:

• Eye drops
• Intravitreal injections
• Periocular injections
• Oral steroids
• IV steroids
• Inhalers
• Nasal sprays
• Skin creams
• Joint injections
• Steroid implants

Patients may not recognize inhalers or skin creams as:

Steroid exposure.

What the Examination Usually Shows

Typical findings include:

• Elevated IOP compared with baseline
• Open anterior chamber angle
• Otherwise relatively quiet anterior segment if there is no underlying inflammatory disease

If glaucoma has developed, the optic nerve may show:

• Neuroretinal rim thinning
• Focal notching
• RNFL defects
• Disc hemorrhage

Gonioscopy Findings

Gonioscopy typically shows:

An open angle

because the mechanism is increased trabecular resistance rather than angle closure.

Gonioscopy is important to exclude:

• Angle closure
• Neovascularization
• Trauma-related angle recession
• Other secondary glaucoma mechanisms

Optic Nerve Evaluation

Look for classic glaucomatous abnormalities including:

• Focal rim thinning
• Superior or inferior notching
• Increased vertical cup-to-disc ratio
• RNFL defects
• Disc hemorrhage

The appearance is generally indistinguishable from:

Primary open-angle glaucoma.

OCT Assessment

Modern structural evaluation includes:

• Peripapillary RNFL OCT
• Macular ganglion cell/inner plexiform layer analysis
• Optic nerve photography when useful

These help establish whether elevated IOP has already caused:

Glaucomatous structural damage.

Visual Field Testing

Standard automated perimetry should be performed when:

• IOP elevation is significant
• The optic nerve appears suspicious
• Pre-existing glaucoma is present

Typical field defects include:

• Nasal step
• Paracentral defect
• Arcuate scotoma

Why Pachymetry Is Useful

Central corneal thickness affects interpretation of:

Applanation IOP

but should not be used as a simple mathematical correction factor.

It contributes to overall glaucoma risk assessment rather than providing a precise “corrected IOP.”

Distinguishing Steroid-Induced Glaucoma From POAG

The two conditions can look almost identical.

Clues favoring a steroid effect include:

• Temporal relationship to corticosteroid exposure
• Previous normal IOP
• IOP reduction after steroid reduction or cessation
• Marked elevation during steroid therapy

Some patients have both:

Underlying POAG plus an additional steroid response.

Distinguishing It From Uveitic Glaucoma

This is a common diagnostic challenge.

A patient being treated for uveitis may have high IOP because of:

Steroid Effect

• Usually open angle
• Often develops after steroid exposure
• Eye may be relatively quiet

Active Uveitis

IOP elevation may result from:

• Trabeculitis
• Inflammatory debris
• Peripheral anterior synechiae
• Pupillary block
• Other inflammatory mechanisms

In many patients:

Both mechanisms contribute simultaneously.

Do Not Stop Necessary Steroids Reflexively

If the patient is being treated for:

• Severe uveitis
• Scleritis
• Postoperative inflammation
• Systemic autoimmune disease

abrupt steroid cessation may be harmful.

The goal is instead to balance:

Inflammatory control and IOP control.

First Management Step

When medically possible:

Reduce, discontinue, or replace the corticosteroid

with a less IOP-provoking alternative.

Possible strategies include:

• Lower dose
• Lower frequency
• Shorter course
• Switch to loteprednol or another lower-risk steroid
• Introduce steroid-sparing therapy for chronic inflammatory disease

This should be coordinated with the clinician treating the underlying condition.

First-Line IOP-Lowering Medication

Treatment generally follows principles used for other open-angle glaucomas.

Common options include:

• Topical beta-blockers
• Topical carbonic anhydrase inhibitors
• Alpha-2 agonists
• Prostaglandin analogues

Choice depends on:

• Magnitude of IOP elevation
• Comorbidities
• Underlying ocular inflammation

Beta-Blockers

Examples include:

• Timolol
• Betaxolol

These reduce aqueous production.

Avoid or use cautiously in patients with:

• Asthma
• Significant COPD
• Bradycardia
• Heart block

Topical Carbonic Anhydrase Inhibitors

Useful agents include:

• Dorzolamide
• Brinzolamide

They reduce aqueous secretion and are frequently used in:

• Steroid-induced ocular hypertension
• Uveitic glaucoma

Alpha-2 Agonists

Brimonidine can provide additional IOP reduction.

Potential limitations include:

• Allergic follicular conjunctivitis
• Fatigue
• Dry mouth

It should generally be avoided in:

Young children

because of CNS depression risk.

Prostaglandin Analogues

Agents such as:

• Latanoprost
• Travoprost
• Bimatoprost
• Tafluprost

are effective IOP-lowering medications and can be used in many patients with steroid-induced glaucoma.

Older concerns that prostaglandins routinely trigger:

• Uveitis
• CME

appear to have been overstated, although caution may still be reasonable in selected patients with:

• Active severe inflammation
• Recent complicated intraocular surgery
• Prior herpetic keratouveitis

Combination Drops

Fixed combinations can improve adherence when multiple medications are required.

Examples include:

• Dorzolamide/timolol
• Brimonidine/timolol
• Brinzolamide/brimonidine

Choice should be individualized.

When Oral Acetazolamide Is Useful

For substantial or rapidly rising IOP, systemic carbonic anhydrase inhibition may be used temporarily.

Acetazolamide can rapidly reduce aqueous production.

Use cautiously in patients with:

• Renal impairment
• Electrolyte disturbances
• Sulfonamide-related severe drug reactions
• Certain metabolic conditions

Hyperosmotic Therapy

Agents such as IV mannitol are:

Not routine therapy for chronic steroid-induced glaucoma

but may be considered for a severe acute IOP crisis when rapid temporary reduction is required.

Selective Laser Trabeculoplasty

SLT can be effective in steroid-induced ocular hypertension or glaucoma, particularly when:

• The angle is open
• Chronic corticosteroid exposure must continue
• Medication burden is high

It can reduce dependence on topical therapy.

Why SLT Can Be Especially Useful

The trabecular meshwork is the primary site of steroid-induced outflow resistance.

SLT can therefore improve:

Trabecular aqueous outflow

without requiring steroid withdrawal.

Its effectiveness varies among patients.

When Surgery Is Needed

Surgery is considered when IOP remains uncontrolled despite:

• Steroid modification
• Medical therapy
• Laser treatment

or when optic nerve damage is advancing.

Surgical Options

Depending on severity and ocular anatomy, options may include:

• Trabeculectomy
• Glaucoma drainage device
• Angle-based procedures/MIGS in selected patients
• Goniotomy or trabeculotomy, particularly in selected pediatric cases

More severe or inflammatory cases may require:

Trabeculectomy or tube-shunt surgery.

MIGS in Steroid-Induced Glaucoma

Because the angle is usually open, selected patients may benefit from procedures targeting the conventional outflow pathway.

These may include:

• Trabecular bypass
• Goniotomy
• Trabeculotomy-based procedures

They are most appropriate when:

• Disease is not extremely advanced
• Target IOP is compatible with MIGS capability

Monitoring Before Starting Steroids

Whenever significant or prolonged corticosteroid therapy is planned, ideally document:

• Baseline IOP
• Optic nerve status
• Glaucoma history

Baseline OCT and visual fields are useful when:

• Glaucoma already exists
• Long-term potent steroid therapy is anticipated

Monitoring After Starting Topical Steroids

A practical approach is to check IOP:

• At baseline when possible
• After approximately 2–4 weeks
• Again during continued therapy

High-risk patients may need:

Earlier and more frequent monitoring.

There is no single schedule appropriate for every patient.

Monitoring After Depot or Intravitreal Steroids

Patients receiving:

• Intravitreal triamcinolone
• Dexamethasone implant
• Fluocinolone implants
• Periocular depot steroids

may require:

Longer and more frequent surveillance

because IOP elevation can be delayed and prolonged.

Follow-up should reflect the known pharmacologic duration of the particular preparation.

Patients With Existing Glaucoma

If the patient already has glaucoma, management should aim to maintain IOP at or below the individual’s:

Established target pressure

rather than accepting a generic value such as 30 mm Hg.

Even relatively modest IOP elevation may be unacceptable in advanced disease.

Why a Fixed IOP Threshold Is Misleading

Older recommendations sometimes used a universal threshold such as:

IOP <30 mm Hg

for patients without apparent damage.

Modern glaucoma care is more individualized.

Treatment intensity depends on:

• Baseline IOP
• Duration of elevation
• Optic nerve susceptibility
• Existing glaucoma
• Rate of progression
• Age and life expectancy

How Treatment Response Is Followed

Monitor:

• IOP
• Optic nerve appearance
• RNFL/GCC OCT
• Visual fields
• Medication adherence
• Steroid dose and route

In patients on long-term corticosteroids, monitoring should continue even after an initially normal response.

When Urgent Treatment Is Needed

More urgent intervention is appropriate when there is:

• Very high IOP
• Rapid rise from baseline
• Advanced glaucoma
• New visual field loss
• Progressive OCT damage
• Corneal edema from high pressure

Expected Outcome

Prognosis is generally excellent when:

• The IOP rise is detected early
• Steroid exposure is modified
• Pressure is adequately controlled

Steroid-induced ocular hypertension is often:

Reversible

but glaucomatous optic nerve damage is:

Permanent.

When IOP May Remain Elevated

Persistent glaucoma is more likely when:

• Steroid exposure was prolonged
• IOP was markedly elevated
• The patient already had POAG
• Structural optic nerve damage developed

Such patients may require lifelong glaucoma treatment.

Potential Complications

Untreated or inadequately controlled disease can cause:

• RNFL loss
• Progressive optic nerve cupping
• Arcuate visual field defects
• Paracentral field loss
• Peripheral field constriction
• Irreversible visual impairment

High-Yield Takeaways

• Steroid-induced glaucoma is a secondary open-angle glaucoma caused by corticosteroid-related reduction in trabecular aqueous outflow.
• Elevated IOP without optic nerve damage is better termed steroid-induced ocular hypertension.
• Any corticosteroid route can cause an IOP rise, including topical, periocular, intravitreal, systemic, inhaled, intranasal, and periocular dermatologic preparations.
• Major risk factors include pre-existing POAG, ocular hypertension, family history of glaucoma, previous steroid response, high myopia, diabetes, and young age.
• Topical steroid-associated IOP elevation most commonly appears after 2–6 weeks, but susceptible patients may respond much sooner.
• Intravitreal injections and long-acting steroid implants can produce delayed and prolonged IOP elevation.
• More potent steroids such as dexamethasone, prednisolone acetate, and difluprednate generally carry greater risk than agents such as loteprednol.
• The mechanism is primarily increased trabecular meshwork resistance from extracellular matrix, cytoskeletal, and cellular changes.
• The anterior chamber angle is typically open on gonioscopy.
• The optic nerve and visual-field pattern are essentially indistinguishable from primary open-angle glaucoma.
• In uveitis, always distinguish steroid response from inflammation-related IOP elevation; both can coexist.
• The first management step is to reduce, stop, or switch the corticosteroid when medically safe, but necessary anti-inflammatory therapy should not be withdrawn indiscriminately.
• Topical glaucoma therapy commonly includes beta-blockers, carbonic anhydrase inhibitors, alpha-2 agonists, and prostaglandin analogues.
• SLT is an effective option in selected patients, particularly when corticosteroid treatment must continue.
• Refractory disease may require MIGS, trabeculectomy, or a glaucoma drainage device, depending on disease severity.
• Patients starting prolonged ocular corticosteroids should ideally have a baseline IOP and subsequent IOP monitoring, with closer surveillance for high-risk patients.
• A fixed IOP threshold such as 30 mm Hg is not an appropriate universal treatment target; management should be based on individual glaucoma risk and target IOP.
• Steroid-induced IOP elevation may reverse after treatment is stopped, but glaucomatous optic nerve damage is irreversible, making early detection essential.

Ophthalmology – Stargardt Disease

What the Disorder Represents

Stargardt disease is the most common inherited juvenile macular dystrophy and is characterized by progressive dysfunction and degeneration of the:

• Photoreceptors
• Retinal pigment epithelium (RPE)
• Macula

The classic form is:

ABCA4-associated Stargardt disease (STGD1)

and is usually inherited in an:

Autosomal recessive pattern.

Although classically presenting in childhood or adolescence, onset can range from:

• Early childhood
• Teenage years
• Adulthood
• Occasionally late adulthood

Earlier onset generally predicts a more severe course.

How Common It Is

Stargardt disease is uncommon but is the most frequent inherited macular dystrophy.

Estimated prevalence is approximately:

1 in 8,000–10,000 people

although estimates vary by population.

The Main Genetic Cause

The classic disorder is caused by biallelic pathogenic variants in:

ABCA4

on chromosome:

1p22

ABCA4 encodes an ATP-binding cassette transporter located in photoreceptor outer-segment disc membranes.

How It Is Inherited

Classic STGD1 is:

Autosomal recessive

Therefore an affected patient typically has:

• Two pathogenic ABCA4 variants
• One inherited from each parent

Parents are often unaffected carriers.

Siblings have a:

25% recurrence risk when both parents are carriers, assuming classic autosomal recessive inheritance.

Why a Strong Family History Is Often Absent

Because the disorder is usually autosomal recessive:

• Parents are typically unaffected
• Multiple generations may appear unaffected
• Only siblings may be affected

Therefore:

Absence of a family history does not argue strongly against Stargardt disease.

Stargardt-Like Dominant Disorders

Not every Stargardt-like phenotype is caused by ABCA4.

Autosomal dominant macular dystrophies that can resemble Stargardt include disorders associated with:

• ELOVL4
• PROM1
• PRPH2 and other genes

These are genetically distinct from classic:

ABCA4-associated STGD1.

Why ABCA4 Dysfunction Damages the Retina

ABCA4 normally helps remove retinoid by-products from photoreceptor outer-segment discs.

When ABCA4 function is impaired:

Retinoid intermediates accumulate → toxic bisretinoids form → lipofuscin accumulates in the RPE

Important toxic fluorophores include:

A2E and related bisretinoids

which contribute to:

• Oxidative stress
• RPE dysfunction
• Photoreceptor loss

Why the Macula Is Especially Vulnerable

The macula has:

• Very high photoreceptor density
• High visual-cycle activity
• High metabolic demand

This makes the central retina especially susceptible to:

Bisretinoid accumulation and RPE-photoreceptor injury.

What “Fundus Flavimaculatus” Means

Fundus flavimaculatus is an older descriptive term referring to the characteristic widespread yellow-white flecks associated with Stargardt disease.

Historically it was sometimes used for:

• Later-onset disease
• More widespread flecks

Today it is generally regarded as part of the:

Stargardt/ABCA4 disease spectrum

rather than a completely separate condition.

Typical Symptoms

Patients usually present with:

• Progressive central visual loss
• Difficulty reading
• Trouble recognizing faces
• Central or paracentral scotoma
• Reduced contrast sensitivity
• Dyschromatopsia

Photophobia may occur.

Peripheral vision is often relatively preserved early.

How Early Disease Can Be Missed

In early disease, the fundus may appear:

Nearly normal

despite significant central visual complaints.

This historically led some patients to be incorrectly suspected of:

• Functional visual loss
• Malingering

Modern OCT and fundus autofluorescence greatly reduce this diagnostic problem.

Early Macular Appearance

The earliest visible changes may include:

• Subtle foveal RPE mottling
• Loss of the normal foveal reflex
• Mild central pigmentary disturbance

A classic description is:

“Beaten-bronze” macular appearance

although this is not present in every patient.

Characteristic Flecks

The classic lesions are:

Yellow-white pisciform flecks

located at the level of the:

• RPE
• Outer retina

They may appear:

• Fish-shaped
• Irregular
• Round
• Elongated

and often extend beyond the macula.

How Flecks Change Over Time

Flecks may initially appear:

• Bright
• Yellow-white
• Hyperautofluorescent

As they involute they may become:

• Less visible
• Hypoautofluorescent
• Associated with local RPE atrophy

Advanced Macular Disease

With progression, patients can develop:

• Macular RPE atrophy
• Photoreceptor loss
• Geographic atrophy-like lesions
• Bull’s-eye maculopathy

Central atrophy may become extensive.

Foveal Sparing

Some patients, especially with later-onset disease, develop:

Foveal sparing

where parafoveal atrophy surrounds a relatively preserved central fovea.

These patients may retain:

• Better visual acuity
• Central fixation

for longer than expected from the extent of surrounding atrophy.

The Most Useful Modern Imaging Tests

The key investigations are:

• Fundus autofluorescence (FAF)
• Optical coherence tomography (OCT)

They provide far more information than fluorescein angiography alone.

Fundus Autofluorescence Findings

FAF is particularly useful because lipofuscin-related fluorophores accumulate within the RPE.

Typical findings include:

• Hyperautofluorescent flecks
• Hypoautofluorescent areas of established RPE atrophy
• Mixed speckled autofluorescence around the macula

FAF often shows:

More extensive disease than is visible clinically.

Why Hyperautofluorescence Occurs

Areas of increased autofluorescence generally correspond to:

• Increased lipofuscin-related fluorophores
• Stressed RPE

whereas:

Hypoautofluorescence

usually corresponds to:

• RPE loss
• Advanced atrophy

OCT Findings

Spectral-domain OCT can demonstrate:

• Ellipsoid-zone disruption
• Outer-segment loss
• Outer nuclear layer thinning
• RPE irregularity
• Progressive outer retinal atrophy

Advanced disease may show complete loss of:

• Photoreceptors
• RPE

within the affected macula.

OCT as a Progression Marker

Serial OCT can document progression through changes in:

• Ellipsoid-zone width
• Outer retinal thickness
• RPE atrophy
• Foveal preservation

It is especially useful for monitoring:

Structural disease progression over time.

The Classic “Dark Choroid”

Fluorescein angiography may demonstrate:

Dark or silent choroid

where the normal background choroidal fluorescence is reduced.

This occurs because lipofuscin-rich RPE blocks:

Choroidal fluorescence.

How Useful Is the Dark Choroid?

The dark choroid is:

• Characteristic
• Historically important

but it is:

Not present in every patient

and its absence does not exclude Stargardt disease.

FA is therefore no longer required routinely when modern multimodal imaging already establishes the phenotype.

Fluorescein Angiography Findings

FA may show:

• Dark choroid
• Hyperfluorescent window defects from RPE atrophy
• Fleck-related staining
• Areas of macular atrophy

It is most useful when:

• CNV is suspected
• The diagnosis remains uncertain

Full-Field ERG

The full-field ERG may be:

Normal in macula-limited disease

because most peripheral retinal function remains preserved.

However, some patients develop generalized retinal dysfunction.

ERG and Prognostic Subgroups

A useful functional classification includes:

Group 1

• Macular dysfunction only
• Normal full-field ERG

Group 2

• Macular disease plus generalized cone dysfunction

Group 3

• Generalized cone and rod dysfunction

Groups with generalized ERG abnormalities generally have:

More extensive disease and poorer prognosis.

Multifocal ERG

Multifocal ERG can demonstrate:

• Reduced central responses
• Regional macular dysfunction

It can be useful when:

• The fundus appearance is subtle
• Central dysfunction needs objective confirmation

but is not required in every patient.

Genetic Testing Is Now Important

An important modern correction is:

Genetic testing is now routinely useful and often recommended in suspected Stargardt disease.

Modern inherited retinal disease panels can identify pathogenic variants in:

• ABCA4
• Other macular dystrophy genes

This helps with:

• Confirming diagnosis
• Distinguishing phenocopies
• Genetic counseling
• Trial eligibility

Why ABCA4 Testing Can Be Complex

ABCA4 is highly polymorphic and has:

• Many pathogenic variants
• Hypomorphic alleles
• Deep intronic variants
• Complex genotype-phenotype relationships

Therefore results should ideally be interpreted with:

Inherited retinal disease genetic counseling.

Important Diagnostic Alternatives

Conditions that may resemble Stargardt disease include:

• Cone dystrophy
• Cone-rod dystrophy
• Pattern dystrophy
• PRPH2-associated macular dystrophy
• Best disease
• Central areolar choroidal dystrophy
• Hydroxychloroquine toxicity
• Bull’s-eye maculopathy from other causes

White-Dot and Flecked Retina Mimics

Conditions with retinal flecks include:

• Fundus albipunctatus
• Retinitis punctata albescens
• Bietti crystalline dystrophy
• Pattern dystrophy

The distribution and associated functional findings help differentiate them.

Distinguishing It From Fundus Albipunctatus

Stargardt Disease

• Central visual loss
• Macular atrophy
• Pisciform flecks
• ABCA4-related in classic disease

Fundus Albipunctatus

• Predominant night blindness
• Numerous white dots
• Often relatively preserved central acuity early
• Usually associated with RDH5

Distinguishing It From Cone or Cone-Rod Dystrophy

Cone-dominant disease often produces:

• Severe photophobia
• Marked color vision loss
• Generalized cone ERG abnormalities

Stargardt disease may have relatively preserved full-field ERG early.

Distinguishing It From Hydroxychloroquine Toxicity

Hydroxychloroquine toxicity may produce:

• Bull’s-eye maculopathy
• Parafoveal outer retinal loss

but history of drug exposure and characteristic OCT/field distribution help separate it from inherited Stargardt disease.

Is There a Curative Treatment?

At present:

There is no approved therapy proven to halt or reverse ABCA4-associated Stargardt disease.

Management is focused on:

• Visual rehabilitation
• Genetic counseling
• Monitoring
• Clinical trial consideration

Avoiding Excess Vitamin A

Because ABCA4 disease involves abnormal handling of vitamin A derivatives, patients are generally advised to:

Avoid high-dose vitamin A supplementation

unless there is a separate medically documented indication.

This does not mean avoiding normal dietary vitamin A.

Light Protection

Many clinicians recommend:

• Sunglasses
• Avoidance of unnecessary intense light exposure

because experimental data suggest that light may contribute to bisretinoid-mediated toxicity.

However:

There is no definitive evidence that routine sunglasses substantially alter the long-term disease course.

They remain reasonable for:

• Comfort
• Photophobia
• General retinal light protection

Low-Vision Rehabilitation

Low-vision services are extremely important once central vision becomes impaired.

Useful aids include:

• High-add reading lenses
• Electronic magnification
• Screen enlargement
• Text-to-speech software
• Contrast enhancement
• Portable video magnifiers

Educational and Occupational Support

Younger patients may benefit from:

• Preferential classroom seating
• Electronic textbooks
• Enlarged print
• Extra examination time
• Accessibility software

Early rehabilitation can maintain independence despite central visual loss.

Managing Choroidal Neovascularization

CNV is uncommon but can occur in areas of macular atrophy.

If CNV develops, treatment with:

Intravitreal anti-VEGF therapy

is appropriate.

Emerging Therapies

Research strategies include:

• Gene-based therapy
• RNA-based approaches
• Visual-cycle modulation
• Complement/inflammation modulation
• Cell-based therapy
• Pharmacologic reduction of toxic bisretinoid accumulation

These remain:

Investigational

and are not yet standard treatment.

Why ABCA4 Gene Therapy Is Challenging

ABCA4 is a relatively large gene, making delivery with conventional:

AAV vectors

technically difficult.

Strategies under investigation include:

• Dual-vector systems
• Alternative viral vectors
• Nonviral delivery
• RNA-based approaches

Monitoring Over Time

Follow-up is individualized but typically includes:

• Visual acuity
• OCT
• FAF
• Color vision or visual field testing when useful
• Low-vision needs

Annual review is reasonable for many stable patients, with closer follow-up when:

• Progression is rapid
• New symptoms arise
• CNV is suspected

What Patients Should Report Promptly

New:

• Sudden central blur
• Metamorphopsia
• New central distortion
• Rapid change in scotoma

should prompt evaluation for:

CNV or another superimposed macular complication.

Expected Disease Course

The natural history is highly variable.

Some patients develop rapid central vision loss in childhood, whereas others maintain useful central vision into adulthood.

In general:

Earlier onset tends to correlate with more severe and widespread retinal degeneration.

Visual Acuity Does Not Follow One Fixed Endpoint

Older teaching suggested that vision inevitably stabilizes around:

• 20/200
• 20/400

This is an oversimplification.

Final acuity varies widely according to:

• Age of onset
• Genotype
• Foveal involvement
• Presence of foveal sparing
• Extent of atrophy

Peripheral Vision

Peripheral visual function is often:

Well preserved in early STGD1

because disease initially concentrates in the macula.

Patients with advanced generalized ABCA4 disease may eventually develop:

• Peripheral retinal dysfunction
• Cone-rod dystrophy phenotype

Long-Term Complications

Potential consequences include:

• Progressive central vision loss
• Central scotoma
• Dyschromatopsia
• Photophobia
• RPE and photoreceptor atrophy
• Rare CNV
• Generalized cone-rod dysfunction in severe disease

High-Yield Takeaways

• Stargardt disease is the most common inherited juvenile macular dystrophy and is usually caused by biallelic ABCA4 variants.
• Classic STGD1 is autosomal recessive, so a strong multigenerational family history is often absent.
• ABCA4 dysfunction causes accumulation of toxic bisretinoids and lipofuscin within the RPE.
• The classic fundus findings are beaten-bronze macular change, yellow-white pisciform flecks, and progressive macular atrophy.
• Fundus flavimaculatus is an older descriptive term within the Stargardt spectrum rather than a clearly separate disease.
• Early disease can have a nearly normal fundus despite substantial visual symptoms.
• FAF and OCT are the key modern imaging modalities.
• FAF commonly shows hyperautofluorescent flecks and hypoautofluorescent RPE atrophy.
• OCT demonstrates ellipsoid-zone disruption, outer retinal loss, and progressive RPE atrophy.
• The classic dark choroid on fluorescein angiography is characteristic but not always present.
• Full-field ERG is often normal in macula-limited disease but may become abnormal when disease extends into generalized cone or cone-rod dysfunction.
• Contrary to older teaching, genetic testing is now an important part of diagnosis and counseling, usually through inherited retinal disease panels.
• Patients should generally avoid high-dose vitamin A supplements, although normal dietary vitamin A does not need to be eliminated.
• There is currently no approved disease-modifying treatment, but gene, RNA, pharmacologic, and cell-based therapies remain under investigation.
• Low-vision rehabilitation and educational support can substantially improve function and independence.
• Secondary CNV, although uncommon, should be treated with intravitreal anti-VEGF therapy.
• Visual prognosis is highly variable; there is no universal endpoint such as 20/200 or 20/400.
• Earlier-onset disease generally carries a worse prognosis, while later-onset disease may show foveal sparing and relatively preserved central vision for longer.

Ophthalmology – Solar Retinopathy

What the Injury Represents

Solar retinopathy is a phototoxic maculopathy caused by direct viewing of the sun or other intense light sources.

Damage is concentrated at the:

• Foveal photoreceptors
• Outer retina
• Retinal pigment epithelium (RPE)

The typical consequence is:

Bilateral central or paracentral visual disturbance after intense solar exposure.

It is also called:

• Solar maculopathy
• Eclipse retinopathy
• Photic retinopathy

Situations That Commonly Cause It

Typical exposures include:

• Looking directly at a solar eclipse
• Deliberate sun gazing
• Prolonged staring at the sun
• Religious or ritual sun viewing
• Psychiatric or drug-associated sun gazing

Similar photic injury can occur from:

• High-intensity welding arcs
• Powerful lasers
• Certain operating microscopes or ophthalmic light sources

although these are not strictly solar retinopathy.

Who Is at Greater Risk

Risk may be increased by:

• Direct unprotected solar viewing
• Repeated or prolonged exposure
• Clear optical media
• Aphakia
• Pharmacologic mydriasis
• Certain photosensitizing medications

Historically proposed risk factors include:

• Tetracycline-class drugs
• Psychedelic/hallucinogenic drug use
• Occupations involving prolonged sky observation

The most important risk factor remains:

Direct fixation on the sun.

Why Eclipses Are Particularly Dangerous

During a partial solar eclipse, ambient light becomes dimmer and the patient may:

• Experience less discomfort
• Maintain fixation longer
• Dilate the pupils somewhat

This can increase retinal exposure.

Importantly:

The sun is not intrinsically more damaging during an eclipse; the danger comes from prolonged unprotected viewing.

How the Retina Is Damaged

The principal mechanism is:

Photochemical injury

rather than a simple thermal burn.

Absorbed light generates:

• Reactive oxygen species
• Oxidative stress
• Photoreceptor outer-segment injury
• RPE damage

The outer retina is particularly vulnerable because the fovea receives highly concentrated light through the ocular optical system.

Important Modern Correction About Ultraviolet Light

Although older descriptions emphasized ultraviolet radiation, most ultraviolet light is absorbed by the:

• Cornea
• Crystalline lens

before reaching the retina.

Retinal phototoxicity is therefore primarily related to:

Visible and near-visible short-wavelength light reaching the macula.

Why the Fovea Is Preferentially Injured

The eye focuses incident light onto a very small retinal area.

The fovea is therefore exposed to a disproportionately high concentration of energy during:

Direct solar fixation.

This produces focal injury of:

• Photoreceptor outer segments
• Ellipsoid zone
• Interdigitation zone
• RPE

Typical Symptom Onset

Symptoms usually develop:

• Within hours
• Sometimes within 1–2 days

after exposure.

The patient may not experience pain during the exposure itself.

What Patients Notice

Common symptoms include:

• Blurred central vision
• Central scotoma
• Paracentral scotoma
• Metamorphopsia
• Dyschromatopsia
• Micropsia
• Reduced contrast sensitivity
• Photophobia

Disease is often:

Bilateral

but may be asymmetric depending on fixation behavior.

Typical Visual Acuity

Visual acuity may range from nearly normal to moderately reduced.

Some patients maintain relatively good Snellen acuity but still complain of:

• Persistent central blur
• Distortion
• Small scotoma

Therefore visual acuity alone may underestimate:

Functional macular damage.

Early Fundus Appearance

Early after injury, the macula may show:

• Small yellow-white foveal spot
• Subtle grayish discoloration
• Fine pigmentary change

The lesion may be extremely subtle.

In some patients:

The fundus initially appears almost normal.

Later Fundus Appearance

After several weeks, the acute yellow lesion may disappear.

Chronic findings range from:

• Normal-appearing macula
• Mild pigment mottling
• Focal RPE disturbance
• Small reddish foveal lesion
• Pseudohole-like appearance

These findings may persist despite improvement in acuity.

The Most Useful Imaging Test

Optical coherence tomography (OCT) is the key investigation.

It is more sensitive than ophthalmoscopy for detecting solar macular injury.

Acute OCT Findings

Early OCT may show:

• Focal hyperreflectivity involving the foveal outer retina
• Disruption of the ellipsoid zone
• Involvement of the outer nuclear layer
• RPE-level abnormalities

In more acute injury, hyperreflectivity may transiently extend into:

Inner retinal layers.

Chronic OCT Findings

Later OCT commonly shows:

• Persistent ellipsoid-zone disruption
• Interdigitation-zone loss
• Focal outer retinal thinning
• Small foveal hyporeflective defect
• RPE irregularity

A characteristic chronic finding is:

A focal outer-retinal defect centered at the fovea.

Why the Older “IS/OS Junction” Term Has Changed

Older OCT descriptions referred to damage at the:

Photoreceptor inner segment–outer segment junction

The modern term is:

Ellipsoid zone

which more accurately describes the corresponding OCT reflectivity band.

Fundus Autofluorescence

FAF may show:

• Subtle central hyperautofluorescence
• Hypoautofluorescent areas if RPE loss develops

Findings are variable, so FAF is mainly:

Supportive rather than diagnostic.

Fluorescein Angiography

FA is often:

Normal

especially early.

Later disease may show:

• Window defects
• Mild RPE transmission hyperfluorescence

Because FA often contributes little, it is generally less useful than:

OCT.

OCT Angiography

OCTA is usually not required.

Solar retinopathy primarily affects:

• Photoreceptors
• RPE

rather than retinal or choroidal vasculature.

OCTA may be considered only if another vascular macular disorder is suspected.

Visual Field Testing

Automated perimetry or microperimetry may demonstrate:

• Central scotoma
• Paracentral sensitivity loss

These defects can persist even after Snellen acuity improves.

Microperimetry

Microperimetry can be particularly helpful for:

• Quantifying central sensitivity loss
• Correlating functional deficit with OCT abnormalities

It is not necessary in routine uncomplicated cases.

Pathologic Changes

Histopathologic and experimental studies demonstrate injury primarily involving:

Photoreceptors

• Outer-segment swelling
• Disc disorganization
• Fragmentation
• Photoreceptor degeneration

RPE

• Pigmentary disruption
• Cellular injury
• Focal atrophy

The damage is concentrated in:

Foveal and parafoveal regions.

How the Diagnosis Is Made

Diagnosis usually rests on:

1. Compatible history of intense light exposure
2. Typical central visual symptoms
3. Characteristic outer retinal changes on OCT

No laboratory testing is required in a classic case.

Key History Questions

Ask about:

• Eclipse viewing
• Sun gazing
• Welding exposure
• Laser exposure
• Duration of exposure
• Protective eyewear
• Recreational drug use
• Psychiatric history where relevant
• Photosensitizing medications

The exposure history may initially be:

Unreported unless specifically asked.

Conditions That Can Look Similar

Important differential diagnoses include:

• Macular hole
• Early lamellar macular hole
• Macular telangiectasia type 2
• Acute macular neuroretinopathy
• Paracentral acute middle maculopathy
• Cone dystrophy
• Stargardt disease
• Central serous chorioretinopathy
• Age-related macular degeneration
• Laser-induced maculopathy

Distinguishing It From a Macular Hole

Solar retinopathy may produce a small central OCT defect that resembles a:

Lamellar or early macular hole

However, the history of photic exposure and predominant:

• Ellipsoid-zone disruption
• Outer retinal injury

favor solar retinopathy.

Distinguishing It From Laser Injury

Laser pointer or industrial laser injury can produce:

• Central scotoma
• Outer retinal disruption
• Macular pigmentary change

but the exposure history is different and hemorrhage may occur with high-energy laser injury.

Is There a Proven Treatment?

There is currently:

No proven treatment that reverses solar retinopathy.

Management is generally:

• Observation
• Reassurance
• Documentation with OCT
• Prevention of repeat exposure

Role of Corticosteroids

Systemic or local corticosteroids have occasionally been used historically, but:

There is no convincing evidence that steroids improve visual outcome in uncomplicated solar retinopathy.

Routine steroid treatment is therefore not recommended.

Why Observation Is Usually Appropriate

Most patients experience spontaneous improvement because:

• Acute outer retinal swelling resolves
• Surviving photoreceptors recover function
• Central sensitivity partially returns

Recovery is typically greatest during the:

First weeks to months.

Suggested Monitoring

Follow-up can include:

• Visual acuity
• Amsler grid symptoms
• OCT

An initial reassessment after several weeks is often sufficient in uncomplicated disease.

More frequent review is appropriate when:

• Diagnosis is uncertain
• Visual acuity worsens
• OCT findings are atypical

A rigid monthly schedule is not necessary for every patient.

Expected Visual Recovery

The prognosis is generally:

Favorable

Most patients recover useful central vision over:

• Weeks
• Several months

Final acuity may approach baseline even when OCT remains abnormal.

What Can Persist

Despite improvement in visual acuity, some patients continue to notice:

• Central scotoma
• Metamorphopsia
• Reduced contrast
• Dyschromatopsia
• Photophobia

These symptoms correlate with persistent outer retinal damage.

Features Linked to a Worse Outcome

Less complete recovery is more likely when there is:

• Severe initial visual loss
• Extensive ellipsoid-zone damage
• RPE atrophy
• Repeated solar exposure
• Large or dense central scotoma

Long-Term Structural Changes

Persistent abnormalities may include:

• Ellipsoid-zone loss
• Outer retinal thinning
• RPE mottling
• Small central atrophic defect

Severe permanent vision loss is uncommon after a single uncomplicated exposure.

Preventing Solar Retinopathy

The most important intervention is:

Never look directly at the sun without appropriate certified solar filters.

Ordinary sunglasses are:

Not adequate for direct solar viewing.

Safe Eclipse Viewing

For direct viewing of a partial solar eclipse, use:

Eclipse viewers or handheld solar filters that meet ISO 12312-2 requirements

and follow manufacturer safety instructions.

Safe alternatives include:

• Pinhole projection
• Other indirect projection techniques

What Should Never Be Used for Direct Solar Viewing

Do not rely on:

• Regular sunglasses
• Multiple stacked sunglasses
• Smoked glass
• Photographic film
• CDs/DVDs
• Homemade filters

These may reduce visible brightness without adequately blocking hazardous radiation.

Binoculars and Telescopes Require Special Care

Never look at the sun through:

• Binoculars
• Telescopes
• Camera lenses

unless an appropriate:

Solar filter is securely mounted over the front aperture of the optical device.

Concentrated sunlight can cause severe retinal injury almost immediately.

Possible Long-Term Problems

Complications are uncommon but may include:

• Persistent central scotoma
• Permanent metamorphopsia
• Dyschromatopsia
• Focal photoreceptor loss
• RPE atrophy
• Permanent reduction in central vision

The principal complication is:

Residual foveal photoreceptor damage.

High-Yield Takeaways

• Solar retinopathy is phototoxic injury of the foveal photoreceptors and RPE caused by direct viewing of the sun or another intense light source.
• The classic setting is unprotected eclipse viewing or deliberate sun gazing.
• Injury is primarily photochemical rather than thermal.
• The key retinal structures affected are the outer retina, ellipsoid zone, photoreceptor outer segments, and RPE.
• Symptoms include central blur, central/paracentral scotoma, metamorphopsia, dyschromatopsia, and reduced contrast sensitivity.
• Disease is typically bilateral but may be asymmetric.
• Early fundus examination may show a small yellow-white foveal spot, but the retina can look almost normal.
• OCT is the most useful diagnostic test and typically demonstrates focal outer-retinal and ellipsoid-zone disruption.
• The older OCT term “IS/OS junction” has largely been replaced by ellipsoid zone.
• Fluorescein angiography is frequently normal and is usually less useful than OCT.
• No laboratory investigation is required when the exposure history and OCT appearance are typical.
• There is no proven specific treatment; most cases are managed with observation and avoidance of further exposure.
• Routine corticosteroids are not supported by convincing evidence.
• Most patients experience substantial visual improvement over weeks to months, although a central scotoma or metamorphopsia may persist.
• Normal or near-normal Snellen acuity does not exclude persistent functional impairment.
• Ordinary sunglasses are not safe for direct solar viewing.
• Proper eclipse viewing requires ISO 12312-2-compliant solar viewers or a safe indirect projection method.
• The best treatment is prevention: direct solar fixation should always be avoided without an appropriate solar filter.

Ophthalmology – Sjögren’s Syndrome

What the Disease Represents

Sjögren’s syndrome, increasingly referred to as Sjögren disease, is a chronic systemic autoimmune disorder characterized by lymphocytic inflammation of the exocrine glands, particularly the:

• Lacrimal glands
• Salivary glands

The classic clinical combination is:

Aqueous-deficient dry eye + xerostomia

However, Sjögren disease is not simply a dry-eye disorder. It can affect multiple organ systems, including:

• Lungs
• Kidneys
• Peripheral and central nervous systems
• Skin
• Blood vessels
• Liver
• Musculoskeletal system
• Hematologic system

A major long-term concern is an increased risk of:

B-cell non-Hodgkin lymphoma.

Who Is Most Commonly Affected

Sjögren disease occurs predominantly in:

• Women
• Usually during middle age

Women are affected far more often than men.

However, the disease can occur:

• In younger adults
• In older adults
• Rarely in children

Why the Glands Stop Functioning

The precise initiating cause is unknown.

The current model involves:

Genetic susceptibility + environmental or infectious trigger → autoimmune activation → B- and T-cell-mediated glandular inflammation

This leads to:

• Lymphocytic infiltration
• Acinar cell dysfunction
• Progressive exocrine gland damage
• Reduced tear and saliva production

The Main Ocular Mechanism

The principal ophthalmic manifestation is:

Severe aqueous-deficient dry eye

because inflammation reduces lacrimal gland secretion.

This causes:

• Tear-film hyperosmolarity
• Ocular surface inflammation
• Epithelial damage
• Neuropathic symptoms in selected patients

Primary and Associated Disease

Historically, Sjögren was divided into:

• Primary Sjögren syndrome — occurring independently
• Secondary Sjögren syndrome — occurring with another autoimmune disease

The term “secondary Sjögren” is now used less consistently because Sjögren disease can coexist with another autoimmune condition without being merely secondary to it.

Common accompanying autoimmune disorders include:

• Rheumatoid arthritis
• Systemic lupus erythematosus
• Systemic sclerosis
• Autoimmune thyroid disease
• Mixed connective tissue disease
• Autoimmune liver disease

Typical Eye Complaints

Patients may report:

• Burning
• Grittiness
• Foreign-body sensation
• Stinging
• Intermittent blurred vision
• Photophobia
• Excessive reflex tearing
• Difficulty wearing contact lenses
• Frequent need for artificial tears

Symptoms may worsen with:

• Reading
• Computer use
• Air conditioning
• Wind
• Low humidity

Typical Oral Complaints

Ask specifically about:

• Persistent dry mouth
• Difficulty swallowing dry food
• Need to sip water while eating
• Frequent dental caries
• Oral candidiasis
• Difficulty speaking for long periods
• Recurrent salivary gland swelling

Parotid enlargement may occur intermittently.

Systemic Clues That Support the Diagnosis

Other symptoms may include:

• Severe fatigue
• Arthralgia
• Arthritis
• Raynaud phenomenon
• Peripheral neuropathy
• Purpura or vasculitic lesions
• Chronic cough or dyspnea
• Renal abnormalities
• Recurrent parotid swelling

These can help distinguish Sjögren disease from uncomplicated age-related dry eye.

Eyelid and Tear-Film Assessment

Examine for coexisting:

• Meibomian gland dysfunction
• Blepharitis
• Incomplete blink
• Lid malposition

Sjögren patients may have both:

Aqueous-deficient and evaporative dry eye

so treating only one mechanism may leave significant symptoms.

Tear Meniscus Findings

The tear meniscus is often:

• Reduced
• Thin
• Difficult to visualize

This reflects decreased aqueous production.

Tear Break-Up Time

Tear-film break-up time may be shortened because of:

• Tear instability
• Mucin abnormalities
• Coexisting MGD

However, tear break-up time alone is:

Not specific for Sjögren disease.

Ocular Surface Staining

Corneal and conjunctival epithelial damage can be demonstrated with:

• Fluorescein
• Lissamine green

Lissamine green is generally better tolerated than older rose bengal staining.

Typical staining is often most prominent in the:

• Interpalpebral conjunctiva
• Inferior cornea
• Nasal and temporal bulbar conjunctiva

Schirmer Testing

The Schirmer I test without anesthesia measures:

• Basal tear secretion
• Reflex tearing

A result of:

≤5 mm wetting in 5 minutes

supports significant aqueous tear deficiency and contributes to current classification criteria.

Why Schirmer Is Not Enough by Itself

A low Schirmer result can occur in:

• Other forms of aqueous-deficient dry eye
• Older age
• Medication-related dry eye

Therefore:

Sjögren disease cannot be diagnosed by Schirmer testing alone.

Modern Classification Framework

The commonly used 2016 ACR/EULAR classification criteria use a weighted scoring system.

Important components include:

• Anti-Ro/SSA positivity
• Labial salivary gland biopsy showing focal lymphocytic sialadenitis with focus score ≥1
• Ocular surface staining
• Schirmer ≤5 mm/5 min
• Reduced unstimulated whole salivary flow

A total score of:

≥4

in an appropriate patient supports classification as Sjögren disease.

The Most Important Autoantibody

The key serologic marker is:

Anti-Ro/SSA

It carries substantially more diagnostic weight than many other autoimmune markers.

Role of Anti-La/SSB

Anti-La/SSB may occur with Sjögren disease, but:

Anti-SSB positivity alone is not part of the current ACR/EULAR classification criteria.

It is therefore supportive rather than independently diagnostic.

ANA and Rheumatoid Factor

Patients commonly have:

• Positive ANA
• Positive rheumatoid factor

but these tests are:

Nonspecific

and are not sufficient to establish the diagnosis.

Salivary Gland Biopsy

A minor labial salivary gland biopsy may demonstrate:

Focal lymphocytic sialadenitis

with clusters of lymphocytes surrounding ducts.

A focus score of:

≥1 focus per 4 mm²

is an important diagnostic criterion.

When Biopsy Is Especially Useful

Minor salivary gland biopsy is particularly helpful when:

• Anti-SSA is negative
• Clinical suspicion remains high
• Classification is uncertain

It is generally preferred to lacrimal gland biopsy because it is:

• Less invasive
• More standardized

Salivary Gland Ultrasound

Ultrasound of the major salivary glands is increasingly used to identify:

• Heterogeneous echotexture
• Hypoechoic areas
• Glandular structural damage

It is useful as an adjunct but is not yet universally incorporated into formal classification criteria.

Tests No Longer Central to Routine Diagnosis

Older approaches relied more heavily on:

• Salivary scintigraphy
• Parotid sialography
• Rose bengal scoring

These may still be useful in selected settings but are less central than:

• Anti-SSA
• Salivary gland biopsy
• Ocular staining
• Schirmer testing
• Salivary flow measurement

Dry Eye Conditions That Can Mimic Sjögren

Important alternatives include:

• Age-related dry eye
• Medication-induced dry eye
• Meibomian gland dysfunction
• Blepharitis
• Exposure keratopathy
• Thyroid eye disease
• Vitamin A deficiency
• Neurotrophic keratopathy
• Graft-versus-host disease

Causes of Dry Mouth That Can Mimic Sjögren

These include:

• Anticholinergic medications
• Antidepressants
• Antihistamines
• Dehydration
• Mouth breathing
• Head and neck radiation
• Diabetes
• Salivary gland disease

Medication review is therefore essential.

Infiltrative Conditions to Exclude

Dry eye and lacrimal gland abnormalities can also occur with:

• Sarcoidosis
• IgG4-related disease
• Amyloidosis
• Lymphoma

These become particularly important when there is:

• Marked gland enlargement
• Atypical orbital findings
• Unusual systemic features

First Step in Ocular Treatment

Management usually begins with:

Preservative-free artificial tears

especially when drops are needed frequently.

Additional lubrication may include:

• Gels
• Ointments at night

Why Preservative-Free Drops Matter

Frequent exposure to preservatives, especially benzalkonium chloride, can worsen:

• Surface toxicity
• Epithelial inflammation
• Dry-eye symptoms

Patients requiring drops more than a few times daily generally benefit from:

Preservative-free formulations.

Controlling Ocular Surface Inflammation

Because Sjögren dry eye is inflammatory, lubrication alone may be insufficient.

Long-term anti-inflammatory therapy may include:

• Topical cyclosporine
• Lifitegrast
• Other approved immunomodulatory dry-eye agents depending on availability

Topical Cyclosporine

Cyclosporine can:

• Reduce T-cell-mediated ocular surface inflammation
• Improve tear production in some patients
• Improve staining over time

Patients should be counseled that:

• Burning on instillation can occur
• Improvement may require several weeks to months

Short Courses of Topical Steroid

A topical corticosteroid may be useful for:

• Moderate-to-severe inflammatory flares
• Rapid control while slower immunomodulators begin working

Long-term unsupervised steroid use should be avoided because of:

• IOP elevation
• Glaucoma
• Cataract
• Infection

Managing Meibomian Gland Dysfunction

If MGD coexists, treatment may include:

• Warm compresses
• Lid hygiene
• Meibomian gland expression
• Appropriate topical therapy
• Selected oral tetracycline-class therapy for rosacea/MGD

Treating MGD can significantly improve:

Tear-film stability even when aqueous deficiency persists.

Filamentary Keratitis

Severe aqueous deficiency may produce:

Filamentary keratitis

Symptoms include:

• Foreign-body sensation
• Sharp pain
• Photophobia

Management may include:

• Intensive lubrication
• Mechanical filament removal
• Hypertonic or mucolytic therapy
• N-acetylcysteine in selected cases
• Bandage or scleral lens in refractory cases

Autologous Serum Tears

For severe ocular surface disease, autologous serum tears can provide:

• Growth factors
• Vitamin A
• Epitheliotrophic components

They may help with:

• Persistent epithelial disease
• Severe staining
• Refractory symptoms

Platelet-Based Eye Drops

Selected centers also use:

• Platelet-rich plasma
• Plasma rich in growth factors

for severe refractory ocular surface disease.

Availability and protocols vary.

Punctal Occlusion

Punctal plugs or cautery can reduce tear drainage.

They may be useful when there is significant:

Aqueous deficiency

However, significant ocular surface inflammation should ideally be controlled first because occlusion may retain:

Inflammatory tear-film mediators.

Scleral Lenses

Severe Sjögren dry eye may benefit greatly from:

Scleral contact lenses

which create a fluid reservoir over the cornea.

They can:

• Protect the epithelium
• Improve comfort
• Improve vision
• Reduce exposure

They are particularly useful in advanced ocular surface disease.

Moisture Conservation

Helpful environmental measures include:

• Humidifiers
• Avoiding direct fan or air-conditioning airflow
• Wraparound moisture-chamber glasses
• Frequent blinking during screen use

These measures improve comfort but do not modify the systemic autoimmune disease.

Evidence for Omega-3 Supplements

Older recommendations commonly advised:

• Fish oil
• Flaxseed oil

However, modern evidence for omega-3 supplementation in dry eye is:

Mixed and not sufficiently consistent to regard it as a standard Sjögren dry-eye treatment.

A normal balanced diet remains appropriate.

Severe Corneal Disease

Advanced ocular surface failure may cause:

• Persistent epithelial defect
• Sterile corneal melt
• Microbial keratitis
• Corneal scarring

These situations require:

Urgent ophthalmic treatment.

When Tarsorrhaphy Is Needed

Temporary or permanent tarsorrhaphy may be considered in severe cases with:

• Persistent epithelial breakdown
• Exposure
• Corneal thinning
• Failure of intensive medical therapy

This is usually reserved for:

Advanced ocular surface disease.

Managing Dry Mouth

Systemic measures may include:

• Frequent water intake
• Sugar-free gum
• Saliva substitutes
• Intensive dental care

Muscarinic agonists can stimulate salivary secretion.

Pilocarpine and Cevimeline

Oral secretagogues include:

• Pilocarpine
• Cevimeline

They may improve:

• Xerostomia
• Occasionally ocular dryness

Potential adverse effects include:

• Sweating
• Flushing
• Urinary frequency
• Gastrointestinal symptoms

They are contraindicated or used cautiously in selected cardiopulmonary conditions.

Why Medication Review Matters

Drugs with anticholinergic effects can worsen both:

• Dry eye
• Dry mouth

Examples include some:

• Antihistamines
• Antidepressants
• Bladder medications
• Antipsychotics

Medication changes should be coordinated with the prescribing clinician.

Systemic Immunomodulatory Therapy

Systemic therapy is determined by the:

Extraglandular manifestations

rather than dry eye alone.

Agents may include:

• Hydroxychloroquine
• Methotrexate
• Mycophenolate
• Azathioprine
• Corticosteroids
• Rituximab or other biologics in selected severe disease

Management is usually coordinated by:

Rheumatology.

Hydroxychloroquine and the Eye

Patients taking long-term hydroxychloroquine require:

Retinal toxicity screening

according to current dosing and screening recommendations.

Hydroxychloroquine is not primarily a treatment for ocular surface dryness.

Systemic Problems Worth Screening For

Sjögren disease may involve:

• Interstitial lung disease
• Peripheral neuropathy
• Renal tubular acidosis
• Glomerular disease
• Vasculitis
• Autoimmune liver disease
• Thyroid disease
• Cytopenias

Persistent systemic symptoms warrant multidisciplinary evaluation.

The Lymphoma Connection

Patients with Sjögren disease have a substantially increased risk of:

B-cell non-Hodgkin lymphoma, especially mucosa-associated lymphoid tissue lymphoma.

The absolute lifetime risk is commonly estimated at roughly:

5–10%, depending on the population and risk profile.

Features That Raise Lymphoma Concern

Concerning features include:

• Persistent major salivary gland enlargement
• Lymphadenopathy
• Splenomegaly
• Palpable purpura
• Cryoglobulinemia
• Low complement, particularly C4
• Monoclonal gammopathy
• Unexplained weight loss or fever

These warrant prompt systemic assessment.

Pregnancy and Anti-Ro/SSA Antibodies

Maternal anti-Ro/SSA antibodies can cross the placenta and cause:

Neonatal lupus

The most important complication is:

Congenital heart block

The risk in a first anti-Ro-positive pregnancy is relatively low, but recurrence risk is much higher after a previously affected pregnancy.

Pregnancy Monitoring

Anti-Ro/SSA-positive pregnant patients should receive:

• Maternal-fetal medicine assessment
• Appropriate fetal cardiac surveillance

Management should be individualized according to:

• Antibody status
• Prior pregnancy history
• Rheumatologic disease activity

Sjögren Disease in Children

Pediatric Sjögren disease is uncommon.

Children may present differently from adults, particularly with:

Recurrent parotid gland swelling

before developing prominent:

• Dry eye
• Dry mouth

Therefore classic adult sicca symptoms may be absent early.

When Ophthalmology Should Suspect Sjögren Disease

Consider systemic evaluation when dry eye is:

• Severe
• Clearly aqueous deficient
• Disproportionate to age
• Refractory to routine treatment
• Associated with dry mouth
• Associated with systemic autoimmune symptoms

Ophthalmologists may be the first clinicians to recognize the disease.

When Rheumatology Referral Is Appropriate

Referral is appropriate when there is:

• Strong Sjögren suspicion
• Positive anti-SSA
• Significant xerostomia
• Arthritis
• Vasculitic symptoms
• Neuropathy
• Pulmonary or renal disease

Diagnosis and long-term systemic management are best handled:

Multidisciplinarily.

Follow-Up Strategy

Ophthalmic follow-up depends on severity rather than a fixed schedule for every patient.

Monitor:

• Visual acuity
• Corneal staining
• Conjunctival staining
• Tear production
• Tear stability
• MGD
• Corneal integrity
• IOP when corticosteroids are used

Severe disease requires more frequent review.

Expected Ocular Course

Sjögren dry eye is:

Chronic

but symptoms and surface damage can often be substantially improved with:

• Lubrication
• Anti-inflammatory therapy
• Tear conservation
• Serum tears
• Scleral lenses

The disease itself is not currently curable.

Factors That Threaten Vision

Most patients retain good vision, but serious complications may occur with severe ocular surface disease, including:

• Persistent epithelial defects
• Infectious keratitis
• Sterile corneal melt
• Corneal ulceration
• Scarring
• Rare perforation

Rapid worsening of pain, redness, or vision requires urgent examination.

High-Yield Takeaways

• Sjögren disease is a systemic autoimmune disorder causing lymphocytic injury to the lacrimal and salivary glands, producing aqueous-deficient dry eye and xerostomia.
• Severe or refractory dry eye associated with dry mouth, fatigue, arthritis, recurrent parotid swelling, or systemic autoimmune symptoms should raise suspicion for Sjögren disease.
• Ocular surface examination commonly shows reduced tear meniscus, corneal/conjunctival staining, and low Schirmer values.
• Schirmer ≤5 mm in 5 minutes contributes to modern classification but is not diagnostic by itself.
• Current ACR/EULAR classification emphasizes anti-Ro/SSA antibodies, minor salivary gland biopsy, ocular staining, Schirmer testing, and reduced salivary flow.
• Anti-SSA is the key serologic marker; isolated anti-SSB positivity is no longer sufficient for classification.
• ANA and rheumatoid factor are common but nonspecific.
• First-line ocular management includes preservative-free lubrication and treatment of coexisting MGD.
• Chronic inflammatory dry eye often benefits from topical cyclosporine, lifitegrast, or another approved anti-inflammatory dry-eye therapy.
• Short courses of topical corticosteroid can control flares but require monitoring for IOP elevation and cataract.
• Severe disease may require autologous serum tears, punctal occlusion, scleral lenses, or occasionally tarsorrhaphy.
• Punctal occlusion is often best performed after significant surface inflammation has been controlled.
• Omega-3 supplementation has inconsistent evidence and should not be considered an established Sjögren-specific treatment.
• The major corneal threats are epithelial breakdown, sterile melt, microbial keratitis, scarring, and rarely perforation.
• Sjögren disease is systemic: pulmonary, renal, neurologic, vascular, and hematologic involvement may occur.
• Patients have an increased risk of B-cell lymphoma, particularly with persistent gland enlargement, cryoglobulinemia, low C4, purpura, or lymphadenopathy.
• Anti-Ro/SSA-positive pregnancy carries a risk of neonatal lupus and congenital heart block, warranting maternal-fetal medicine involvement.
• Pediatric disease may initially present with recurrent parotitis rather than classic sicca symptoms.
• Long-term care is best coordinated between ophthalmology, rheumatology, dentistry/oral medicine, and other specialists according to systemic involvement.

Who Is Most Commonly Affected Sjögren disease occurs predominantly in:  Women Usually during middle age  Women are affected far more often than men. However, the disease can occur:  In younger adults In older adults Rarely in children

Why the Glands Stop Functioning The precise initiating cause is unknown. The current model involves: Genetic susceptibility + environmental or infectious trigger → autoimmune activation → B- and T-cell-mediated glandular inflammation This leads to:  Lymphocytic infiltration Acinar cell dysfunction Progressive exocrine gland damage Reduced tear and saliva production

The Main Ocular Mechanism The principal ophthalmic manifestation is: Severe aqueous-deficient dry eye because inflammation reduces lacrimal gland secretion. This causes:  Tear-film hyperosmolarity Ocular surface inflammation Epithelial damage Neuropathic symptoms in selected patients

Primary and Associated Disease Historically, Sjögren was divided into:  Primary Sjögren syndrome — occurring independently Secondary Sjögren syndrome — occurring with another autoimmune disease  The term “secondary Sjögren” is now used less consistently because Sjögren disease can coexist with another autoimmune condition without being merely secondary to it. Common accompanying autoimmune disorders include:  Rheumatoid arthritis Systemic lupus erythematosus Systemic sclerosis Autoimmune thyroid disease Mixed connective tissue disease Autoimmune liver disease

Typical Eye Complaints Patients may report:  Burning Grittiness Foreign-body sensation Stinging Intermittent blurred vision Photophobia Excessive reflex tearing Difficulty wearing contact lenses Frequent need for artificial tears  Symptoms may worsen with:  Reading Computer use Air conditioning Wind Low humidity

Typical Oral Complaints Ask specifically about:  Persistent dry mouth Difficulty swallowing dry food Need to sip water while eating Frequent dental caries Oral candidiasis Difficulty speaking for long periods Recurrent salivary gland swelling  Parotid enlargement may occur intermittently.

Systemic Clues That Support the Diagnosis Other symptoms may include:  Severe fatigue Arthralgia Arthritis Raynaud phenomenon Peripheral neuropathy Purpura or vasculitic lesions Chronic cough or dyspnea Renal abnormalities Recurrent parotid swelling  These can help distinguish Sjögren disease from uncomplicated age-related dry eye.

Eyelid and Tear-Film Assessment Examine for coexisting:  Meibomian gland dysfunction Blepharitis Incomplete blink Lid malposition  Sjögren patients may have both: Aqueous-deficient and evaporative dry eye so treating only one mechanism may leave significant symptoms.

Tear Meniscus Findings The tear meniscus is often:  Reduced Thin Difficult to visualize  This reflects decreased aqueous production.

Tear Break-Up Time Tear-film break-up time may be shortened because of:  Tear instability Mucin abnormalities Coexisting MGD  However, tear break-up time alone is: Not specific for Sjögren disease.

Ocular Surface Staining Corneal and conjunctival epithelial damage can be demonstrated with:  Fluorescein Lissamine green  Lissamine green is generally better tolerated than older rose bengal staining. Typical staining is often most prominent in the:  Interpalpebral conjunctiva Inferior cornea Nasal and temporal bulbar conjunctiva

Schirmer Testing The Schirmer I test without anesthesia measures:  Basal tear secretion Reflex tearing  A result of: ≤5 mm wetting in 5 minutes supports significant aqueous tear deficiency and contributes to current classification criteria.

Why Schirmer Is Not Enough by Itself A low Schirmer result can occur in:  Other forms of aqueous-deficient dry eye Older age Medication-related dry eye  Therefore: Sjögren disease cannot be diagnosed by Schirmer testing alone.

Modern Classification Framework The commonly used 2016 ACR/EULAR classification criteria use a weighted scoring system. Important components include:  Anti-Ro/SSA positivity Labial salivary gland biopsy showing focal lymphocytic sialadenitis with focus score ≥1 Ocular surface staining Schirmer ≤5 mm/5 min Reduced unstimulated whole salivary flow  A total score of: ≥4 in an appropriate patient supports classification as Sjögren disease.

The Most Important Autoantibody The key serologic marker is: Anti-Ro/SSA It carries substantially more diagnostic weight than many other autoimmune markers.

Role of Anti-La/SSB Anti-La/SSB may occur with Sjögren disease, but: Anti-SSB positivity alone is not part of the current ACR/EULAR classification criteria. It is therefore supportive rather than independently diagnostic.

ANA and Rheumatoid Factor Patients commonly have:  Positive ANA Positive rheumatoid factor  but these tests are: Nonspecific and are not sufficient to establish the diagnosis.

Salivary Gland Biopsy A minor labial salivary gland biopsy may demonstrate: Focal lymphocytic sialadenitis with clusters of lymphocytes surrounding ducts. A focus score of: ≥1 focus per 4 mm² is an important diagnostic criterion.

When Biopsy Is Especially Useful Minor salivary gland biopsy is particularly helpful when:  Anti-SSA is negative Clinical suspicion remains high Classification is uncertain  It is generally preferred to lacrimal gland biopsy because it is:  Less invasive More standardized

Salivary Gland Ultrasound Ultrasound of the major salivary glands is increasingly used to identify:  Heterogeneous echotexture Hypoechoic areas Glandular structural damage  It is useful as an adjunct but is not yet universally incorporated into formal classification criteria.

Tests No Longer Central to Routine Diagnosis Older approaches relied more heavily on:  Salivary scintigraphy Parotid sialography Rose bengal scoring  These may still be useful in selected settings but are less central than:  Anti-SSA Salivary gland biopsy Ocular staining Schirmer testing Salivary flow measurement

Dry Eye Conditions That Can Mimic Sjögren Important alternatives include:  Age-related dry eye Medication-induced dry eye Meibomian gland dysfunction Blepharitis Exposure keratopathy Thyroid eye disease Vitamin A deficiency Neurotrophic keratopathy Graft-versus-host disease

Causes of Dry Mouth That Can Mimic Sjögren These include:  Anticholinergic medications Antidepressants Antihistamines Dehydration Mouth breathing Head and neck radiation Diabetes Salivary gland disease  Medication review is therefore essential.

Infiltrative Conditions to Exclude Dry eye and lacrimal gland abnormalities can also occur with:  Sarcoidosis IgG4-related disease Amyloidosis Lymphoma  These become particularly important when there is:  Marked gland enlargement Atypical orbital findings Unusual systemic features

First Step in Ocular Treatment Management usually begins with: Preservative-free artificial tears especially when drops are needed frequently. Additional lubrication may include:  Gels Ointments at night

Why Preservative-Free Drops Matter Frequent exposure to preservatives, especially benzalkonium chloride, can worsen:  Surface toxicity Epithelial inflammation Dry-eye symptoms  Patients requiring drops more than a few times daily generally benefit from: Preservative-free formulations.

Controlling Ocular Surface Inflammation Because Sjögren dry eye is inflammatory, lubrication alone may be insufficient. Long-term anti-inflammatory therapy may include:  Topical cyclosporine Lifitegrast Other approved immunomodulatory dry-eye agents depending on availability

Topical Cyclosporine Cyclosporine can:  Reduce T-cell-mediated ocular surface inflammation Improve tear production in some patients Improve staining over time  Patients should be counseled that:  Burning on instillation can occur Improvement may require several weeks to months

Short Courses of Topical Steroid A topical corticosteroid may be useful for:  Moderate-to-severe inflammatory flares Rapid control while slower immunomodulators begin working  Long-term unsupervised steroid use should be avoided because of:  IOP elevation Glaucoma Cataract Infection

Managing Meibomian Gland Dysfunction If MGD coexists, treatment may include:  Warm compresses Lid hygiene Meibomian gland expression Appropriate topical therapy Selected oral tetracycline-class therapy for rosacea/MGD  Treating MGD can significantly improve: Tear-film stability even when aqueous deficiency persists.

Filamentary Keratitis Severe aqueous deficiency may produce: Filamentary keratitis Symptoms include:  Foreign-body sensation Sharp pain Photophobia  Management may include:  Intensive lubrication Mechanical filament removal Hypertonic or mucolytic therapy N-acetylcysteine in selected cases Bandage or scleral lens in refractory cases

Autologous Serum Tears For severe ocular surface disease, autologous serum tears can provide:  Growth factors Vitamin A Epitheliotrophic components  They may help with:  Persistent epithelial disease Severe staining Refractory symptoms

Platelet-Based Eye Drops Selected centers also use:  Platelet-rich plasma Plasma rich in growth factors  for severe refractory ocular surface disease. Availability and protocols vary.

Punctal Occlusion Punctal plugs or cautery can reduce tear drainage. They may be useful when there is significant: Aqueous deficiency However, significant ocular surface inflammation should ideally be controlled first because occlusion may retain: Inflammatory tear-film mediators.

Scleral Lenses Severe Sjögren dry eye may benefit greatly from: Scleral contact lenses which create a fluid reservoir over the cornea. They can:  Protect the epithelium Improve comfort Improve vision Reduce exposure  They are particularly useful in advanced ocular surface disease.

Moisture Conservation Helpful environmental measures include:  Humidifiers Avoiding direct fan or air-conditioning airflow Wraparound moisture-chamber glasses Frequent blinking during screen use  These measures improve comfort but do not modify the systemic autoimmune disease.

Evidence for Omega-3 Supplements Older recommendations commonly advised:  Fish oil Flaxseed oil  However, modern evidence for omega-3 supplementation in dry eye is: Mixed and not sufficiently consistent to regard it as a standard Sjögren dry-eye treatment. A normal balanced diet remains appropriate.

Severe Corneal Disease Advanced ocular surface failure may cause:  Persistent epithelial defect Sterile corneal melt Microbial keratitis Corneal scarring  These situations require: Urgent ophthalmic treatment.

When Tarsorrhaphy Is Needed Temporary or permanent tarsorrhaphy may be considered in severe cases with:  Persistent epithelial breakdown Exposure Corneal thinning Failure of intensive medical therapy  This is usually reserved for: Advanced ocular surface disease.

Managing Dry Mouth Systemic measures may include:  Frequent water intake Sugar-free gum Saliva substitutes Intensive dental care  Muscarinic agonists can stimulate salivary secretion.

Pilocarpine and Cevimeline Oral secretagogues include:  Pilocarpine Cevimeline  They may improve:  Xerostomia Occasionally ocular dryness  Potential adverse effects include:  Sweating Flushing Urinary frequency Gastrointestinal symptoms  They are contraindicated or used cautiously in selected cardiopulmonary conditions.

Why Medication Review Matters Drugs with anticholinergic effects can worsen both:  Dry eye Dry mouth  Examples include some:  Antihistamines Antidepressants Bladder medications Antipsychotics  Medication changes should be coordinated with the prescribing clinician.

Systemic Immunomodulatory Therapy Systemic therapy is determined by the: Extraglandular manifestations rather than dry eye alone. Agents may include:  Hydroxychloroquine Methotrexate Mycophenolate Azathioprine Corticosteroids Rituximab or other biologics in selected severe disease  Management is usually coordinated by: Rheumatology.

Hydroxychloroquine and the Eye Patients taking long-term hydroxychloroquine require: Retinal toxicity screening according to current dosing and screening recommendations. Hydroxychloroquine is not primarily a treatment for ocular surface dryness.

Systemic Problems Worth Screening For Sjögren disease may involve:  Interstitial lung disease Peripheral neuropathy Renal tubular acidosis Glomerular disease Vasculitis Autoimmune liver disease Thyroid disease Cytopenias  Persistent systemic symptoms warrant multidisciplinary evaluation.

The Lymphoma Connection Patients with Sjögren disease have a substantially increased risk of: B-cell non-Hodgkin lymphoma, especially mucosa-associated lymphoid tissue lymphoma. The absolute lifetime risk is commonly estimated at roughly: 5–10%, depending on the population and risk profile.

Features That Raise Lymphoma Concern Concerning features include:  Persistent major salivary gland enlargement Lymphadenopathy Splenomegaly Palpable purpura Cryoglobulinemia Low complement, particularly C4 Monoclonal gammopathy Unexplained weight loss or fever  These warrant prompt systemic assessment.

Pregnancy and Anti-Ro/SSA Antibodies Maternal anti-Ro/SSA antibodies can cross the placenta and cause: Neonatal lupus The most important complication is: Congenital heart block The risk in a first anti-Ro-positive pregnancy is relatively low, but recurrence risk is much higher after a previously affected pregnancy.

Pregnancy Monitoring Anti-Ro/SSA-positive pregnant patients should receive:  Maternal-fetal medicine assessment Appropriate fetal cardiac surveillance  Management should be individualized according to:  Antibody status Prior pregnancy history Rheumatologic disease activity

Sjögren Disease in Children Pediatric Sjögren disease is uncommon. Children may present differently from adults, particularly with: Recurrent parotid gland swelling before developing prominent:  Dry eye Dry mouth  Therefore classic adult sicca symptoms may be absent early.

When Ophthalmology Should Suspect Sjögren Disease Consider systemic evaluation when dry eye is:  Severe Clearly aqueous deficient Disproportionate to age Refractory to routine treatment Associated with dry mouth Associated with systemic autoimmune symptoms  Ophthalmologists may be the first clinicians to recognize the disease.

When Rheumatology Referral Is Appropriate Referral is appropriate when there is:  Strong Sjögren suspicion Positive anti-SSA Significant xerostomia Arthritis Vasculitic symptoms Neuropathy Pulmonary or renal disease  Diagnosis and long-term systemic management are best handled: Multidisciplinarily.

Follow-Up Strategy Ophthalmic follow-up depends on severity rather than a fixed schedule for every patient. Monitor:  Visual acuity Corneal staining Conjunctival staining Tear production Tear stability MGD Corneal integrity IOP when corticosteroids are used  Severe disease requires more frequent review.

Expected Ocular Course Sjögren dry eye is: Chronic but symptoms and surface damage can often be substantially improved with:  Lubrication Anti-inflammatory therapy Tear conservation Serum tears Scleral lenses  The disease itself is not currently curable.

Factors That Threaten Vision Most patients retain good vision, but serious complications may occur with severe ocular surface disease, including:  Persistent epithelial defects Infectious keratitis Sterile corneal melt Corneal ulceration Scarring Rare perforation  Rapid worsening of pain, redness, or vision requires urgent examination.

High-Yield Takeaways  Sjögren disease is a systemic autoimmune disorder causing lymphocytic injury to the lacrimal and salivary glands, producing aqueous-deficient dry eye and xerostomia. Severe or refractory dry eye associated with dry mouth, fatigue, arthritis, recurrent parotid swelling, or systemic autoimmune symptoms should raise suspicion for Sjögren disease. Ocular surface examination commonly shows reduced tear meniscus, corneal/conjunctival staining, and low Schirmer values. Schirmer ≤5 mm in 5 minutes contributes to modern classification but is not diagnostic by itself. Current ACR/EULAR classification emphasizes anti-Ro/SSA antibodies, minor salivary gland biopsy, ocular staining, Schirmer testing, and reduced salivary flow. Anti-SSA is the key serologic marker; isolated anti-SSB positivity is no longer sufficient for classification. ANA and rheumatoid factor are common but nonspecific. First-line ocular management includes preservative-free lubrication and treatment of coexisting MGD. Chronic inflammatory dry eye often benefits from topical cyclosporine, lifitegrast, or another approved anti-inflammatory dry-eye therapy. Short courses of topical corticosteroid can control flares but require monitoring for IOP elevation and cataract. Severe disease may require autologous serum tears, punctal occlusion, scleral lenses, or occasionally tarsorrhaphy. Punctal occlusion is often best performed after significant surface inflammation has been controlled. Omega-3 supplementation has inconsistent evidence and should not be considered an established Sjögren-specific treatment. The major corneal threats are epithelial breakdown, sterile melt, microbial keratitis, scarring, and rarely perforation. Sjögren disease is systemic: pulmonary, renal, neurologic, vascular, and hematologic involvement may occur. Patients have an increased risk of B-cell lymphoma, particularly with persistent gland enlargement, cryoglobulinemia, low C4, purpura, or lymphadenopathy. Anti-Ro/SSA-positive pregnancy carries a risk of neonatal lupus and congenital heart block, warranting maternal-fetal medicine involvement. Pediatric disease may initially present with recurrent parotitis rather than classic sicca symptoms. Long-term care is best coordinated between ophthalmology, rheumatology, dentistry/oral medicine, and other specialists according to systemic involvement.

Ophthalmology – Seventh Cranial Nerve Palsy

What Facial Nerve Palsy Means

The facial nerve (cranial nerve VII) provides:

• Motor supply to the muscles of facial expression
• Parasympathetic fibers to the lacrimal, submandibular, and sublingual glands
• Taste sensation from the anterior two-thirds of the tongue
• A small amount of general sensory supply to parts of the external ear

Facial nerve dysfunction produces weakness of the ipsilateral facial muscles and, from an ophthalmic perspective, can cause:

• Lagophthalmos
• Reduced blink
• Lower-lid ectropion
• Exposure keratopathy
• Corneal ulceration in severe cases

The most common acute peripheral facial palsy is:

Bell palsy

The Typical Bell Palsy Pattern

Bell palsy is an:

Acute idiopathic peripheral facial nerve palsy

characterized by unilateral weakness involving:

• Forehead
• Eyelid closure
• Lower facial muscles

Symptoms usually evolve over:

Hours to a few days

Additional features may include:

• Postauricular discomfort
• Altered taste
• Hyperacusis
• Reduced tearing
• Altered salivation

Bell palsy remains a:

Diagnosis of exclusion

when atypical features are present.

Why the Eye Is at Risk

Normal facial nerve function is essential for:

• Forceful eyelid closure
• Spontaneous blinking
• Effective tear-film distribution
• Lacrimal pump function

When the orbicularis oculi becomes weak:

The cornea may remain exposed between blinks and during sleep.

This can cause:

• Punctate epithelial erosions
• Persistent epithelial defect
• Microbial keratitis
• Corneal scarring
• Rare perforation

Mapping Facial Nerve Function

Important facial nerve components include:

Motor Fibers

Supply:

• Frontalis
• Orbicularis oculi
• Muscles of facial expression
• Stapedius
• Stylohyoid
• Posterior belly of digastric

Parasympathetic Fibers

Supply:

• Lacrimal gland
• Submandibular gland
• Sublingual gland
• Nasal and palatal glands

Taste Fibers

Carry taste from the:

Anterior two-thirds of the tongue

through the chorda tympani.

Central Versus Peripheral Weakness

One of the first localization questions is whether facial weakness is:

• Supranuclear/central
• Peripheral lower motor neuron

Typical Central Facial Weakness

A unilateral supranuclear lesion usually produces weakness that is most obvious in the:

Contralateral lower face

because upper facial muscles receive substantial bilateral cortical innervation.

The patient may retain relatively good ability to:

• Raise the eyebrows
• Wrinkle the forehead
• Close the eyes

However, forehead sparing is:

A useful clinical clue, not an absolute rule.

Stroke and other central lesions can occasionally produce some upper facial weakness.

Typical Peripheral Facial Weakness

A peripheral VII nerve lesion generally causes ipsilateral weakness of:

• Forehead
• Eyelid closure
• Lower face

Patients may be unable to:

• Raise the eyebrow
• Close the eye fully
• Smile symmetrically
• Puff the cheek

What to Look for at Rest

Examine for:

• Facial asymmetry
• Reduced blink
• Widened palpebral fissure
• Flattened nasolabial fold
• Lower-lid ectropion
• Brow ptosis
• Lagophthalmos

The affected corner of the mouth may:

Droop downward.

Testing Active Facial Movement

Ask the patient to:

• Raise the eyebrows
• Furrow the brow
• Close the eyes tightly
• Smile
• Show the teeth
• Puff out the cheeks

Compare both sides for:

• Strength
• Symmetry
• Fatigability

Bell Phenomenon

When attempting to close the eyelids, the globe normally rotates:

Upward and slightly outward

This is the:

Bell phenomenon

A good Bell phenomenon provides some protection to the cornea when eyelid closure is incomplete.

A poor or absent Bell phenomenon increases:

Exposure risk.

Corneal Sensation Matters

Corneal sensation should be tested because severe corneal injury risk rises markedly when VII palsy is accompanied by:

Trigeminal V1 dysfunction

The dangerous combination is:

Poor eyelid closure + reduced corneal sensation

because exposure injury may progress with surprisingly little discomfort.

Assessing the Corneal Surface

Look carefully for:

• Inferior punctate epithelial erosions
• Confluent staining
• Persistent epithelial defect
• Stromal thinning
• Corneal infiltrate

Fluorescein staining is essential when significant lagophthalmos is present.

Common Causes of Facial Nerve Palsy

Facial palsy may result from:

• Bell palsy
• Ramsay Hunt syndrome
• Lyme disease
• Stroke
• Brainstem disease
• Cerebellopontine angle tumor
• Temporal bone disease
• Parotid tumor
• Trauma
• Sarcoidosis
• Guillain-Barré syndrome
• Meningitis
• Leukemia/lymphoma
• Metastatic disease

The clinical pattern determines how extensive the work-up should be.

Bell Palsy

Bell palsy is thought to represent acute inflammation and edema of the facial nerve within the:

Facial canal

A viral-triggered inflammatory mechanism, particularly involving herpes-family viruses, has been proposed.

No specific viral infection must be demonstrated to make the diagnosis.

Symptoms That Support Bell Palsy

Typical Bell palsy produces:

• Acute unilateral facial weakness
• Forehead involvement
• Lagophthalmos
• Altered taste
• Hyperacusis
• Mild postauricular discomfort

The palsy should otherwise be:

Neurologically isolated.

Features That Are Not Typical for Simple Bell Palsy

Further investigation is warranted for:

• Gradual progressive weakness
• Bilateral facial palsy
• Recurrent same-side palsy
• Multiple cranial neuropathies
• Significant facial numbness
• Limb weakness
• Ataxia
• Diplopia
• Marked hearing loss
• Vertigo
• Parotid mass
• Constitutional symptoms

Ramsay Hunt Syndrome

Ramsay Hunt syndrome results from reactivation of:

Varicella-zoster virus

in the geniculate ganglion.

Typical features include:

• Peripheral facial palsy
• Severe otalgia
• Vesicles involving the pinna or external auditory canal
• Vesicles on the palate in some patients
• Hearing loss
• Tinnitus
• Vertigo

The facial weakness is often more severe and recovery poorer than in Bell palsy.

When Vesicles Are Absent

Rarely, VZV facial palsy occurs without an obvious rash:

Zoster sine herpete

so the absence of vesicles does not completely exclude a VZV-related palsy.

Lyme-Associated Facial Palsy

Lyme disease can cause:

• Unilateral facial palsy
• Bilateral facial palsy
• Meningitic symptoms
• Other cranial neuropathies

Testing should be based on:

• Geographic exposure
• Tick exposure
• Compatible systemic symptoms

Routine Lyme serology is not necessary in every straightforward Bell palsy.

Bilateral Facial Weakness

Bilateral facial palsy is unusual and should prompt evaluation for systemic or neurologic disease.

Important causes include:

• Guillain-Barré syndrome
• Lyme disease
• Sarcoidosis
• Meningitis
• Leukemia/lymphoma
• HIV
• Other inflammatory neuropathies

Bilateral disease should generally not be labeled:

Idiopathic Bell palsy without further evaluation.

Multiple Cranial Neuropathies

VII palsy accompanied by abnormalities of other cranial nerves raises concern for:

• Skull-base disease
• Brainstem disease
• Meningeal inflammation
• Neoplasm
• Sarcoidosis
• Infection

Particular attention should be given to:

• CN V
• CN VI
• CN VIII

because their involvement can help localize the lesion.

Myasthenia as a Mimic

Myasthenia gravis can produce:

• Facial weakness
• Ptosis
• Diplopia
• Orbicularis weakness

but typically shows:

• Fluctuation
• Fatigability
• Normal pupils

True isolated complete unilateral forehead-to-mouth facial palsy is less typical.

Möbius Syndrome

Möbius syndrome is a congenital cranial dysinnervation disorder characterized by:

• Congenital facial weakness
• Abduction deficits from CN VI involvement

Patients may have:

• Poor facial expression
• Lagophthalmos
• Esotropia
• Feeding difficulties

History That Helps Localize the Lesion

Ask about:

• Speed of onset
• Ear pain
• Vesicles
• Hearing change
• Tinnitus
• Vertigo
• Taste disturbance
• Dry eye
• Facial numbness
• Diplopia
• Dysarthria
• Dysphagia
• Limb weakness
• Ataxia
• Recent infection
• Trauma
• Cancer history

How Bell Palsy Is Diagnosed

Typical Bell palsy is diagnosed:

Clinically

when there is:

• Acute onset
• Unilateral peripheral VII weakness
• No other neurologic deficit
• No obvious alternative cause

Routine extensive laboratory testing or imaging is:

Not required in an otherwise typical presentation.

When Imaging Is Appropriate

MRI brain/internal auditory canals with contrast should be considered when there is:

• Progressive or insidious onset
• No improvement over the expected interval
• Recurrent ipsilateral palsy
• Bilateral palsy
• Multiple cranial neuropathies
• Hearing loss
• Vestibular symptoms
• Suspicion of tumor or brainstem disease

Imaging After Trauma

For temporal bone trauma:

CT of the temporal bones

is generally more useful for defining:

• Fracture
• Bony facial canal injury

MRI may be added when soft-tissue or intracranial pathology is suspected.

Laboratory Testing Should Be Targeted

Routine broad laboratory screening is usually unnecessary for uncomplicated Bell palsy.

Testing should instead follow clinical suspicion.

Possible studies include:

• Glucose/HbA1c
• Lyme serology
• Syphilis serology
• HIV testing
• ACE or other sarcoid evaluation
• Inflammatory markers

depending on the presentation.

Electrodiagnostic Assessment

Electroneurography and EMG are mainly useful in:

• Severe complete palsy
• Prognostication
• Traumatic injury
• Persistent weakness

They are not routinely necessary for mild uncomplicated Bell palsy.

Grading the Severity

The House-Brackmann scale is commonly used to grade facial nerve function from:

• Grade I – normal
• Grade VI – complete paralysis

Documenting severity helps assess:

• Progression
• Recovery
• Prognosis

First Priority – Protect the Cornea

From an ophthalmic perspective, immediate management focuses on:

Preventing exposure keratopathy

especially when eyelid closure is incomplete.

Daytime Surface Protection

Use:

• Frequent preservative-free artificial tears

Frequency depends on exposure severity and may need to be:

• Every 1–2 hours
• More frequently in severe exposure

Night-Time Protection

At bedtime, use:

• Lubricating ophthalmic ointment
• Eyelid taping if appropriate
• Moisture chamber

The aim is to maintain complete corneal coverage throughout sleep.

Eyelid Taping

If taping is used:

• The upper lid should be gently closed
• Tape should not abrade the cornea
• The eye should be checked after application

Improper taping can paradoxically:

Worsen exposure.

Treating Bell Palsy

For adults with Bell palsy, the most effective disease-modifying treatment is:

Early oral corticosteroid therapy

ideally started within:

72 hours of symptom onset.

Corticosteroid Regimens

Common approaches use:

• Prednisone/prednisolone approximately 50–60 mg daily

followed by:

• Short course
• With or without taper

Exact regimen varies by guideline and patient factors.

Why Steroids Are Important

Early corticosteroids improve the likelihood of:

Complete facial motor recovery

and reduce long-term:

• Weakness
• Synkinesis

when started promptly.

Role of Antiviral Therapy

Antiviral therapy should:

Not be used alone for routine Bell palsy.

Valacyclovir or acyclovir may be offered in addition to corticosteroids, particularly in:

• Severe palsy
• Complete paralysis
• Cases where herpetic involvement is strongly suspected

Any additional benefit over steroids alone is likely:

Modest.

Treating Ramsay Hunt Syndrome

Ramsay Hunt syndrome generally warrants early:

• Systemic antiviral therapy
• Systemic corticosteroid therapy

when medically appropriate.

ENT involvement may be useful when there is:

• Hearing loss
• Severe vertigo
• Extensive otologic disease

Diabetes and Steroid Treatment

Patients with diabetes receiving systemic corticosteroids should have:

Glucose monitored closely

because steroid therapy may produce substantial hyperglycemia.

When Lubrication Is Not Enough

If corneal exposure remains significant despite medical protection, options include:

• Temporary tarsorrhaphy
• Botulinum toxin-induced protective ptosis in selected cases
• Upper-eyelid loading
• Lower-lid tightening
• Scleral/contact lens protection in selected patients

Temporary Tarsorrhaphy

A temporary tarsorrhaphy reduces the exposed ocular surface and is especially useful when:

• Epithelial breakdown is developing
• Recovery of facial function is expected
• Conservative measures are inadequate

Upper Eyelid Loading

For persistent paralytic lagophthalmos, a weight can be implanted in the upper eyelid.

Options include:

• Platinum
• Gold

Platinum weights are often favored because they can be:

• Thinner
• Lower profile

for a similar functional effect.

Lower-Lid Malposition

Facial palsy may cause:

• Lower-lid ectropion
• Retraction
• Punctal eversion

Surgical management may include:

• Lateral canthal tightening
• Midface support
• Other lower-lid reconstructive procedures

When Corneal Disease Requires Urgent Review

Urgent ophthalmic care is needed for:

• Persistent epithelial defect
• Corneal infiltrate
• Stromal thinning
• Ulceration
• Reduced corneal sensation
• Severe pain or sudden visual decline

These may signal:

Impending sight-threatening corneal disease.

Facial Nerve Decompression

Routine surgical decompression for Bell palsy is:

Not recommended

because evidence of benefit is insufficient and procedural morbidity can be substantial.

Facial Nerve Trauma

When there is known:

• Facial nerve transection
• Severe temporal bone trauma

early ENT/neurosurgical assessment may be needed for:

• Exploration
• Repair
• Nerve grafting

depending on the injury.

Aberrant Reinnervation

During recovery, regenerating facial fibers may reconnect abnormally.

This can produce:

Synkinesis

such as:

• Eye closure when smiling
• Mouth movement when blinking

Crocodile Tears

Aberrant regeneration can misdirect salivary-related parasympathetic fibers toward the lacrimal gland.

This produces:

Gustatory lacrimation

or:

Crocodile tears

where eating triggers excessive tearing.

Hemifacial Spasm and Synkinesis Management

Botulinum toxin can be useful for:

• Facial synkinesis
• Hemifacial spasm
• Hyperkinetic facial contractions

Specialized facial rehabilitation may also improve function.

Facial Neuromuscular Rehabilitation

Patients with persistent weakness or synkinesis may benefit from:

• Facial retraining
• Neuromuscular re-education
• Biofeedback

This differs from nonspecific electrical stimulation, for which evidence is less convincing.

Follow-Up After Bell Palsy

For uncomplicated disease, reassessment is usually appropriate within:

A few weeks

with earlier ophthalmic follow-up when:

• Lagophthalmos is significant
• Corneal staining exists
• Corneal sensation is reduced

When Lack of Recovery Is Concerning

Reconsider the diagnosis if:

• Weakness continues to worsen beyond the usual early phase
• No meaningful recovery develops over several months
• Facial function progressively declines
• New cranial neuropathies appear

These features may require:

MRI and specialist reassessment.

Expected Recovery

Most patients with Bell palsy have:

Good to excellent recovery

particularly when weakness is incomplete.

Recovery often begins within:

• Several weeks

and continues over:

• Several months

Features Favoring Better Recovery

Better prognosis is associated with:

• Incomplete palsy
• Early improvement
• Younger age
• Preserved facial motor responses

Features Associated With Less Complete Recovery

Less favorable prognosis is associated with:

• Complete facial paralysis
• Older age
• Delayed recovery
• Severe axonal degeneration
• Ramsay Hunt syndrome
• Diabetes in some series

Long-Term Problems

Possible complications include:

• Exposure keratopathy
• Corneal ulceration
• Permanent facial weakness
• Synkinesis
• Crocodile tears
• Hemifacial spasm
• Ectropion
• Chronic tearing
• Facial contracture

The most immediately preventable ophthalmic complication is:

Corneal injury from exposure.

High-Yield Takeaways

• Cranial nerve VII innervates the muscles of facial expression and carries parasympathetic fibers to the lacrimal and salivary glands, as well as taste from the anterior two-thirds of the tongue.
• Bell palsy is an acute unilateral peripheral VII nerve palsy involving both upper and lower facial muscles.
• Central lesions usually cause predominantly contralateral lower facial weakness with relative forehead sparing, but this pattern is not absolute.
• The major ophthalmic danger is lagophthalmos with exposure keratopathy.
• Always assess corneal sensation; combined CN V and VII dysfunction produces particularly high risk of corneal ulceration.
• Typical uncomplicated Bell palsy is a clinical diagnosis and does not require routine MRI or broad laboratory testing.
• Progressive onset, bilateral disease, recurrent ipsilateral palsy, multiple cranial neuropathies, hearing loss, vertigo, or other neurologic signs require further investigation.
• Ramsay Hunt syndrome = peripheral facial palsy + VZV-related otalgia/vesicles ± hearing or vestibular symptoms.
• Bilateral facial palsy should raise concern for conditions such as Lyme disease, Guillain-Barré syndrome, sarcoidosis, or meningitis.
• The key disease-modifying treatment for Bell palsy is oral corticosteroid started within 72 hours whenever appropriate.
• Antiviral therapy is not effective as monotherapy for routine Bell palsy but may be added to steroids in severe or complete palsy.
• Corneal protection includes frequent preservative-free tears, lubricating ointment, eyelid taping, and/or a moisture chamber.
• Persistent exposure may require temporary tarsorrhaphy, upper-eyelid loading, or lower-lid corrective surgery.
• Routine facial nerve decompression is not recommended for uncomplicated Bell palsy.
• Aberrant regeneration can produce synkinesis and crocodile tears, while botulinum toxin is useful for selected chronic hyperkinetic complications.
• Most Bell palsy patients recover well, but protecting the cornea during the period of weakness is the immediate ophthalmic priority.

Ophthalmology – Serpiginous Choroiditis

What the Disorder Represents

Serpiginous choroiditis (SC) is a rare, chronic, recurrent inflammatory chorioretinopathy primarily involving the:

• Choriocapillaris
• Retinal pigment epithelium (RPE)
• Outer retina
• Deeper choroid to a variable degree

The classic lesion begins near the:

Optic disc

and extends outward in an irregular, geographic or snake-like pattern.

Disease is usually:

• Bilateral
• Asymmetric
• Recurrent
• Potentially progressive

Vision is threatened mainly when inflammation involves the:

• Fovea
• Papillomacular region

or when secondary:

Choroidal neovascularization (CNV) develops.

Who Usually Develops It

Serpiginous choroiditis is uncommon and represents only a small proportion of posterior uveitis cases.

It most often affects:

• Young to middle-aged adults
• Men somewhat more frequently in many reported series

There is no consistent:

• Familial pattern
• Racial predilection

Prevalence appears higher in some regions, particularly parts of:

South Asia

where tuberculosis-associated serpiginous-like choroiditis must be carefully considered.

How the Inflammation Behaves

The inflammatory process primarily targets the:

Choriocapillaris–RPE–outer retinal complex

leading to:

• Choriocapillaris nonperfusion
• RPE dysfunction
• Photoreceptor injury
• Subsequent chorioretinal atrophy

Repeated inflammatory episodes produce:

Progressive geographic scars

that frequently extend from the edges of previous lesions.

What Causes It

The exact cause of classic serpiginous choroiditis remains:

Unknown

It is generally regarded as an:

Immune-mediated inflammatory choriocapillaropathy

However, a major modern diagnostic issue is that a similar phenotype can occur with infection, especially:

Mycobacterium tuberculosis

This infectious form is generally termed:

Serpiginous-like choroiditis

rather than classic autoimmune serpiginous choroiditis.

Why Tuberculosis Matters

Tubercular serpiginous-like choroiditis is particularly important in:

• TB-endemic regions
• Patients with TB exposure
• Patients with positive TB testing
• Multifocal or atypical lesions

Treating undiagnosed infectious disease with immunosuppression alone can:

Worsen infection

so infectious causes must be considered before prolonged immunomodulatory treatment.

Genetic Associations

No causative genetic mutation has been established.

Certain HLA associations have been reported, including:

• HLA-B7 in some populations

but these findings are:

Not used routinely for diagnosis.

Typical Symptoms

Patients commonly notice:

• Painless blurred vision
• Metamorphopsia
• Paracentral or central scotoma
• Reduced contrast
• Photopsias

Symptoms are often initially:

Unilateral

even though the fellow eye may later become involved.

Pattern of Recurrence

The disease is characteristically:

Chronic and relapsing

Recurrences often develop:

• At the advancing edge of an old lesion
• Adjacent to previous scars

and may occur after intervals of:

• Weeks
• Months
• Years

Repeated attacks can progressively enlarge the area of:

Chorioretinal atrophy.

What the Anterior Segment Usually Looks Like

The anterior segment is often:

Quiet

although mild anterior chamber inflammation may occasionally occur.

Likewise, vitreous inflammation is generally:

• Minimal
• Mild

Marked vitritis should prompt consideration of another diagnosis, particularly:

• Tubercular serpiginous-like disease
• Multifocal choroiditis
• Infectious posterior uveitis

Classic Peripapillary Form

The most typical form is:

Peripapillary geographic serpiginous choroiditis

Lesions begin adjacent to the optic disc and extend centrifugally in:

• Geographic
• Irregular
• Serpentine

patterns.

Appearance of Active Disease

Active lesions are usually:

• Gray-white
• Cream-colored
• Deep retinal/choroidal

and occur at the:

Leading edge of previously inactive scar

They may appear relatively subtle clinically despite significant choriocapillaris inflammation on imaging.

Appearance After Healing

Healed lesions leave:

• RPE atrophy
• Choroidal atrophy
• Hyperpigmented borders
• Hypopigmented central scar

The resulting lesion may appear:

Geographic and sharply demarcated.

Why Recurrences Are Easy to Recognize

A highly characteristic pattern is:

New creamy active border surrounding or extending from an older pigmented atrophic lesion

This reflects reactivation along the margin of previously affected tissue.

Macular Serpiginous Choroiditis

A less common variant begins in the:

Macula

without direct continuity with the optic disc.

This form has a worse visual prognosis because:

• Foveal involvement occurs early
• CNV risk is higher
• Scar formation directly affects central vision

Amphiginous Choroiditis

Amphiginous choroiditis describes a phenotype with overlapping features of:

• APMPPE
• Serpiginous choroiditis

Patients may initially present with multiple placoid lesions and subsequently develop:

• Recurrent
• Progressive
• Serpiginous-like extension

This entity is often considered within the broader spectrum of:

Placoid inflammatory chorioretinopathies.

Relentless Placoid Chorioretinitis

Relentless placoid chorioretinitis (RPC) is characterized by:

• Numerous placoid lesions
• Involvement extending from posterior pole to far peripheral retina
• Prolonged or recurrent disease course

It differs from classic serpiginous choroiditis by its:

• Much greater number of lesions
• Wider retinal distribution
• More prolonged inflammatory activity

Tubercular Serpiginous-Like Choroiditis

This form may differ from classic SC by showing:

• Multifocal lesions
• More peripheral involvement
• Greater vitritis
• Less strict peripapillary origin
• More prominent inflammation

However, overlap is substantial.

Diagnosis depends on combining:

• Clinical appearance
• TB exposure/risk
• IGRA or other testing
• Chest imaging
• Systemic assessment

No single test proves ocular TB in every case.

Establishing the Diagnosis

Diagnosis is primarily:

Clinical plus multimodal imaging

There is no single laboratory marker for classic serpiginous choroiditis.

Important goals are to:

1. Confirm active choriocapillaris/RPE disease
2. Identify foveal involvement
3. Detect CNV
4. Exclude infection, especially TB and syphilis

Fundus Photography

Color or wide-field photography is useful to document:

• Lesion borders
• Active extension
• Atrophic scars
• Recurrence patterns

Serial images can help demonstrate:

Centrifugal expansion from old lesions.

Fundus Autofluorescence

FAF is particularly useful for identifying activity and monitoring progression.

Active lesions may show:

• Early hypoautofluorescence
• Followed by hyperautofluorescent borders or mixed patterns

Healing lesions become:

Hypoautofluorescent

as RPE atrophy develops.

FAF often reveals lesion activity more clearly than clinical examination alone.

Fluorescein Angiography

Active lesions typically demonstrate:

• Early hypofluorescence
• Late staining or hyperfluorescence

Early hypofluorescence reflects:

• Choriocapillaris nonperfusion
• Blockage by inflammatory material

Late hyperfluorescence reflects:

• Staining
• RPE alteration
• Leakage at active margins

Angiographic Appearance of Old Scars

Inactive atrophic lesions generally show:

• Early transmission hyperfluorescence
• Late staining

depending on the degree of:

• RPE loss
• Choroidal atrophy

Indocyanine Green Angiography

ICGA is particularly sensitive for:

Choroidal and choriocapillaris involvement

Active lesions usually appear as:

• Persistent hypofluorescent areas

and may extend beyond the clinically visible lesion.

This can help determine:

True extent of inflammatory activity.

Optical Coherence Tomography

OCT is essential for assessing:

• Outer retinal disruption
• Ellipsoid-zone loss
• RPE abnormalities
• Subretinal hyperreflective material
• Retinal thinning after healing
• Secondary CNV

OCT During Active Disease

Active lesions may show:

• Hyperreflectivity of outer retinal layers
• Disruption of the ellipsoid zone
• RPE irregularity
• Outer retinal thickening

As inflammation resolves:

• Outer retinal thinning
• RPE atrophy
• Photoreceptor loss

may remain.

OCT Angiography

OCTA may help demonstrate:

• Choriocapillaris flow deficits
• Secondary CNV

It is particularly useful when CNV is suspected but hemorrhage or inflammation complicates conventional angiographic interpretation.

However:

OCTA does not show leakage, so it complements rather than replaces FA.

Visual Field Changes

Visual field defects correspond to areas of chorioretinal damage.

Patients may develop:

• Paracentral scotomas
• Enlarged blind spot
• Central scotoma
• Irregular field loss

Some scotomas may become less dense after active inflammation resolves, but permanent defects can remain after atrophy.

Laboratory Evaluation Strategy

Classic SC has no diagnostic blood test.

Testing is directed toward excluding:

• Tuberculosis
• Syphilis
• Other infectious/inflammatory mimics

rather than confirming idiopathic serpiginous disease.

Tuberculosis Evaluation

Depending on local prevalence and clinical suspicion, evaluation may include:

• IGRA
• Tuberculin skin testing
• Chest X-ray
• Chest CT when needed

A positive IGRA indicates sensitization to TB but does:

Not by itself prove ocular TB.

Syphilis Screening

Syphilis should be excluded because it can mimic virtually any posterior uveitis pattern.

Testing usually includes:

• Treponemal test
• Nontreponemal test

When Additional Systemic Evaluation Is Needed

Further testing may be considered when clinical features suggest:

• Sarcoidosis
• Autoimmune disease
• Other infectious choroiditis

Broad indiscriminate laboratory panels are generally less useful than:

Targeted investigations based on phenotype.

Disorders That Can Look Similar

Important differentials include:

• Tubercular serpiginous-like choroiditis
• APMPPE
• Relentless placoid chorioretinitis
• Multifocal choroiditis
• Toxoplasmosis
• Syphilis
• Sarcoidosis
• Choroidal ischemia
• VKH
• Posterior placoid syphilitic chorioretinitis

Distinguishing It From APMPPE

Serpiginous Choroiditis

• Chronic
• Recurrent
• Often starts peripapillary
• Expands from old scars
• More likely to require prolonged immunosuppression

APMPPE

• Usually acute
• Multiple placoid lesions
• Often self-limited
• Commonly follows viral prodrome
• Recurrence less typical

Distinguishing It From Tubercular Serpiginous-Like Disease

Classic Serpiginous Choroiditis

• Usually peripapillary origin
• Minimal vitritis
• Recurrent edge progression
• Immune-mediated

Tubercular Serpiginous-Like Choroiditis

• Often multifocal
• May involve peripheral retina
• More vitritis
• Associated TB evidence
• Requires antituberculous treatment

Primary Goal of Treatment

The central objective is:

Stop active lesion expansion before the fovea becomes involved and prevent recurrent inflammation.

Because permanent chorioretinal atrophy develops after each episode:

Delayed treatment can produce irreversible visual loss.

Corticosteroid Treatment

Active noninfectious serpiginous choroiditis is commonly treated initially with:

Systemic corticosteroids

especially when lesions threaten:

• Fovea
• Papillomacular bundle

High-dose oral prednisone is commonly used.

Severe or rapidly progressive disease may require:

IV methylprednisolone

for rapid suppression.

Why Steroid Monotherapy Is Often Insufficient

Although corticosteroids can suppress acute activity:

Relapses are common during tapering or after discontinuation.

Therefore recurrent, bilateral, or vision-threatening disease frequently requires:

Early steroid-sparing immunomodulatory therapy.

Long-Term Immunomodulatory Therapy

Common agents include:

• Mycophenolate mofetil
• Methotrexate
• Azathioprine
• Cyclosporine

Choice depends on:

• Disease severity
• Comorbidities
• Treatment response
• Specialist experience

Biologic Therapy

Refractory disease may occasionally require biologic therapy such as:

• Adalimumab
• Infliximab

usually under management by:

• Uveitis specialist
• Rheumatologist

Evidence is less extensive than for more common uveitic disorders, but biologics can be useful in difficult recurrent disease.

Role of Alkylating Agents

Older treatment protocols used:

• Cyclophosphamide
• Chlorambucil

These agents can control severe disease but are now used much less often because of:

• Bone marrow toxicity
• Infertility
• Secondary malignancy risk
• Other serious adverse effects

Local Steroid Therapy

Periocular or intravitreal corticosteroid can reduce local inflammation, but:

Local therapy alone is generally inadequate for bilateral recurrent serpiginous choroiditis.

It may be used selectively as adjunctive treatment.

Managing Tubercular Serpiginous-Like Choroiditis

If tuberculosis is suspected or confirmed, management generally requires:

Appropriate multidrug antituberculous therapy

with infectious-disease or respiratory-medicine collaboration.

Corticosteroids may be added to control ocular inflammation but should generally be used:

Alongside appropriate antimicrobial therapy, not as isolated treatment.

Treating Choroidal Neovascularization

Secondary CNV is an important cause of visual loss.

Modern first-line treatment is:

Intravitreal anti-VEGF therapy

such as:

• Aflibercept
• Ranibizumab
• Bevacizumab

Simultaneous control of active underlying inflammation is also important.

How CNV Presents

Suspect CNV with:

• New metamorphopsia
• New central blur
• Subretinal hemorrhage
• New subretinal/intraretinal fluid
• Hyperreflective neovascular complex on OCT

OCTA and FA can help confirm the diagnosis.

Monitoring During Active Disease

Active lesions require:

Frequent follow-up

because progression toward the fovea can occur quickly.

Monitoring commonly uses:

• Visual acuity
• OCT
• FAF
• Fundus photography
• FA/ICGA when needed

Monitoring During Remission

Even apparently inactive disease requires long-term surveillance because:

Recurrences can occur months or years later.

Patients should report promptly:

• New scotoma
• Metamorphopsia
• Blurred vision
• New photopsias

Expected Long-Term Course

The disease is typically:

Chronic and recurrent

with progressive chorioretinal scarring.

Some patients maintain good vision if:

• Fovea remains uninvolved
• Recurrences are rapidly controlled

Others develop substantial central visual loss through:

• Foveal atrophy
• CNV
• Repeated inflammatory damage

Features Associated With Worse Vision

Poorer prognosis is associated with:

• Macular involvement
• Repeated recurrences
• Delayed suppression of active lesions
• Secondary CNV
• Bilateral progressive disease

Macular serpiginous disease generally carries a worse prognosis than classic peripapillary disease.

Long-Term Complications

Potential complications include:

• Choroidal neovascularization
• Foveal chorioretinal atrophy
• Subretinal fibrosis
• Serous retinal detachment
• Cystoid macular edema
• Retinal vasculitis
• Branch retinal vein occlusion
• Rare anterior uveitis
• Permanent central scotoma

High-Yield Takeaways

• Serpiginous choroiditis is a chronic recurrent inflammatory choriocapillaropathy involving the choriocapillaris, RPE, and outer retina.
• The classic lesion begins peripapillary and spreads centrifugally in a geographic or serpentine pattern.
• Recurrences typically occur at the active edge of an old chorioretinal scar.
• The anterior segment is often quiet and vitreous inflammation is usually mild.
• Macular involvement and secondary CNV are the major threats to central vision.
• Multimodal imaging is essential: FAF, OCT, FA, and ICGA are particularly useful for detecting activity and defining lesion extent.
• Active lesions usually show early hypofluorescence and late staining/hyperfluorescence on FA.
• ICGA commonly demonstrates persistent hypofluorescence corresponding to choriocapillaris involvement.
• OCT shows active outer retinal/RPE disruption and later permanent outer retinal atrophy.
• One of the most important modern distinctions is between classic autoimmune serpiginous choroiditis and tubercular serpiginous-like choroiditis.
• TB-associated disease is especially relevant in endemic regions and should be considered before starting prolonged immunosuppression.
• A positive TB test supports exposure but does not by itself establish ocular tuberculosis.
• Active noninfectious disease generally requires prompt systemic corticosteroid therapy.
• Because recurrences are common with steroid tapering, recurrent or vision-threatening disease often requires steroid-sparing immunomodulatory therapy, such as mycophenolate, methotrexate, azathioprine, or cyclosporine.
• Tubercular serpiginous-like choroiditis requires appropriate antituberculous therapy, with corticosteroid added when needed for inflammatory control.
• Secondary CNV is treated primarily with intravitreal anti-VEGF therapy while controlling the underlying inflammation.
• Long-term surveillance is essential because recurrence may occur months or years after apparent quiescence.
• The final visual outcome depends mainly on whether recurrent inflammation or CNV damages the fovea.

Ophthalmology – Serous (Exudative) Retinal Detachment

What This Retinal Detachment Represents

A serous or exudative retinal detachment (SRD/ERD) occurs when fluid accumulates beneath the neurosensory retina without a retinal break and without vitreoretinal traction as the primary mechanism.

The central process is:

Excess fluid entering the subretinal space or inadequate removal of subretinal fluid by the RPE → separation of neurosensory retina from the retinal pigment epithelium

This distinguishes exudative detachment from:

• Rhegmatogenous retinal detachment
• Tractional retinal detachment

Why Subretinal Fluid Normally Does Not Accumulate

Normally, the retina remains attached because of:

• Active fluid transport by the RPE
• Osmotic forces generated by the choroid
• Intact outer blood-retinal barrier
• Normal choroidal vascular permeability
• Normal retinal vascular barrier function

The RPE continuously pumps:

Fluid from the subretinal space toward the choroid.

How an Exudative Detachment Develops

Subretinal fluid accumulates when one or more mechanisms occur:

• Breakdown of the outer blood-retinal barrier
• Choroidal vascular hyperpermeability
• Severe retinal vascular leakage
• Inflammatory disruption of the RPE
• Tumor-related exudation
• Severe systemic vascular disease
• Failure of normal RPE fluid transport

The Major Etiologic Groups

The main categories are:

• Inflammatory
• Vascular
• Neoplastic
• Choroidal/RPE disorders
• Congenital/developmental
• Iatrogenic

Identifying the underlying cause is more important than treating the fluid in isolation.

Inflammatory Causes

Important inflammatory conditions include:

• Vogt-Koyanagi-Harada disease
• Posterior scleritis
• Sympathetic ophthalmia
• Sarcoidosis
• Systemic lupus erythematosus
• ANCA-associated vasculitis
• Other choroiditis/uveitic disorders

In these conditions, choroidal inflammation and RPE dysfunction can produce:

Multifocal or bullous serous retinal detachments.

Infectious Inflammatory Causes

Infection may occasionally produce exudative retinal detachment through:

• Retinochoroiditis
• Vasculitis
• Choroidal inflammation

Examples include:

• Syphilis
• Tuberculosis
• Toxoplasmosis
• CMV retinitis
• Bartonella infection

The exact infectious evaluation should be guided by the clinical pattern.

Vascular and Hypertensive Causes

Important vascular causes include:

• Malignant hypertension
• Preeclampsia/eclampsia
• Retinal vein occlusion
• Coats disease
• Retinal vascular tumors
• Severe renal disease
• Disseminated intravascular coagulation

The mechanism may involve:

• Choroidal ischemia
• RPE infarction
• Retinal vascular leakage

Preeclampsia and Eclampsia

Severe hypertensive disease of pregnancy can produce:

• Choroidal ischemia
• Elschnig spots
• RPE dysfunction
• Bilateral serous retinal detachments

These detachments often:

Resolve after control of the systemic disease and delivery

with generally favorable visual recovery.

Renal and Systemic Vascular Disease

Exudative retinal detachment may occur with severe:

• Renal failure
• Lupus nephritis
• Hypertensive nephropathy
• Other vasculitic renal disorders

In these cases, the retinal findings may be part of a broader:

Hypertensive or immune-mediated choroidopathy.

Neoplastic Causes

Tumors may produce SRD by:

• Direct exudation
• Choroidal vascular leakage
• RPE dysfunction

Important examples include:

• Choroidal melanoma
• Choroidal metastasis
• Circumscribed choroidal hemangioma
• Choroidal osteoma
• Primary vitreoretinal lymphoma
• Retinoblastoma in children

Why Tumor-Related Detachment Matters

A new unilateral serous detachment associated with:

• Elevated choroidal mass
• Orange pigment
• Subretinal exudation
• Unexplained hemorrhage

should prompt evaluation for:

Underlying ocular neoplasm.

Central Serous Chorioretinopathy

Central serous chorioretinopathy (CSC) is an important cause of localized serous neurosensory detachment.

It is associated with:

• Choroidal hyperpermeability
• Pachychoroid
• RPE leakage

Risk factors include:

• Corticosteroid exposure
• Psychological stress
• Obstructive sleep apnea
• Pregnancy
• Certain sympathomimetic states

Bullous Central Serous Disease

Rarely, severe CSC can produce:

Extensive or bullous exudative retinal detachment

which may mimic:

• Inflammatory disease
• Rhegmatogenous detachment
• Choroidal tumor

Optic Disc Pit Maculopathy

An optic disc pit can be associated with:

• Intraretinal schisis-like cavities
• Subretinal fluid
• Serous macular detachment

Fluid may originate from:

• Vitreous
• Cerebrospinal fluid

although the exact mechanism remains debated.

Uveal Effusion Syndrome

Uveal effusion syndrome can produce:

• Choroidal detachment
• Serous retinal detachment
• Peripheral choroidal elevation

It may occur in:

• Nanophthalmos
• Thickened sclera
• Idiopathic cases

Nanophthalmos

Nanophthalmic eyes have:

• Short axial length
• Thick sclera
• Crowded anterior segment

Impaired vortex vein drainage and reduced transscleral fluid movement can promote:

Uveal effusion and exudative retinal detachment.

Iatrogenic Causes

SRD may occasionally occur after:

• Scleral buckling
• Extensive retinal photocoagulation
• Intraocular surgery
• Severe postoperative inflammation

The mechanism depends on:

• Choroidal congestion
• Inflammation
• RPE dysfunction

What Patients Usually Notice

Symptoms depend on location and cause.

Possible complaints include:

• Blurred vision
• Metamorphopsia
• Relative scotoma
• Peripheral field loss
• Fluctuating vision
• Reduced contrast

Inflammatory causes may additionally produce:

• Pain
• Redness
• Photophobia

Why Symptoms Can Change With Position

Classically, subretinal fluid may:

Shift with changes in head position

because no retinal break constrains the fluid.

This is supportive of an exudative detachment but:

Shifting fluid is not present in every case.

Appearance on Fundus Examination

The detached retina usually appears:

• Smooth
• Dome-shaped
• Elevated
• Relatively transparent

It generally lacks the:

Corrugated mobile folds typical of acute rhegmatogenous detachment.

Associated Findings That Point Toward the Cause

Look for:

Inflammatory Clues

• Anterior chamber cells
• Vitritis
• Choroidal thickening
• Retinal vasculitis

Vascular Clues

• Severe hypertensive changes
• Telangiectasia
• Exudates
• Retinal hemorrhages

Neoplastic Clues

• Choroidal mass
• Orange pigment
• Subretinal deposits

First Diagnostic Priority

The first practical question is:

Is there a retinal break?

A careful peripheral examination is required because an RRD can occasionally appear relatively smooth.

Perform:

Dilated indirect ophthalmoscopy with scleral depression whenever possible.

OCT Evaluation

Optical coherence tomography is the most useful imaging test for documenting subretinal fluid.

OCT can show:

• Neurosensory detachment
• Intraretinal fluid
• RPE abnormalities
• Choroidal folds
• Pachychoroid
• Macular structural damage

Enhanced-depth imaging can assess:

Choroidal thickness.

Fluorescein Angiography

FA helps identify the source and pattern of leakage.

Examples include:

• Pinpoint leaks in CSC
• Multifocal leakage in VKH
• Disc leakage in inflammatory disease
• Vascular leakage in Coats disease
• Tumor-associated leakage

Indocyanine Green Angiography

ICGA is particularly useful for evaluating:

• Choroidal hyperpermeability
• VKH
• CSC
• Choroidal tumors
• Choroidal inflammatory disease

It provides information about:

Choroidal circulation that FA cannot show as well.

Fundus Autofluorescence

FAF can help assess:

• RPE stress
• Chronicity of fluid
• RPE atrophy
• CSC-related damage
• Inflammatory chorioretinal lesions

It is especially useful for chronic disease monitoring.

Role of B-Scan Ultrasound

B-scan is useful when:

• Media opacity prevents fundus visualization
• Posterior scleritis is suspected
• Choroidal mass is suspected
• Choroidal detachment is present

Possible findings include:

• Smooth retinal elevation
• Choroidal thickening
• Posterior scleral thickening
• Intraocular mass

Ultrasound in Posterior Scleritis

Posterior scleritis may show the classic:

T-sign

from fluid in the posterior sub-Tenon space around the optic nerve.

This can strongly support the diagnosis in the appropriate clinical setting.

Imaging in Tumor-Related SRD

If a mass is suspected, evaluation may include:

• B-scan ultrasound
• OCT
• FAF
• FA
• ICGA
• MRI in selected cases

The imaging approach depends on the suspected tumor.

Laboratory Testing Strategy

There is:

No single universal laboratory panel for serous retinal detachment.

Testing should be driven by:

• History
• Ocular phenotype
• Systemic findings

When Inflammation Is Suspected

Possible investigations include:

• CBC
• ESR
• CRP
• ANA
• ANCA
• Renal function
• Urinalysis

depending on the suspected systemic disorder.

When Infection Is a Possibility

Targeted testing may include:

• Syphilis serology
• TB testing
• Toxoplasma testing
• Bartonella testing

Additional studies should be based on exposure and phenotype.

Routine broad infectious panels are generally:

Low yield.

Always Check Blood Pressure

A blood pressure measurement is especially important when there is:

• Bilateral SRD
• Hypertensive retinopathy
• Pregnancy
• Renal disease

because severe hypertension can be:

Vision- and life-threatening.

Important Diagnostic Alternatives

The major retinal detachment differentials are:

• Rhegmatogenous retinal detachment
• Tractional retinal detachment
• Degenerative retinoschisis
• Choroidal detachment

Exudative vs Rhegmatogenous Detachment

Exudative RD

• No retinal break
• No primary traction
• Smooth retinal elevation
• Fluid may shift
• Often associated with inflammation, tumor, or vascular disease

Rhegmatogenous RD

• Full-thickness retinal break
• Vitreoretinal traction
• Corrugated mobile retina
• Often acute flashes/floaters

Exudative vs Tractional Detachment

Exudative RD

• Fluid-driven
• Smooth convex elevation
• No primary traction

Tractional RD

• Caused by fibrovascular membranes
• Concave retinal configuration
• Usually relatively immobile
• Common in proliferative diabetic retinopathy

Exudative RD vs Retinoschisis

Retinoschisis

• Splitting within retinal layers
• Very smooth
• Usually immobile
• Often inferotemporal
• Frequently asymptomatic

Exudative RD

• Fluid beneath the full neurosensory retina
• Often secondary to systemic or choroidal disease

The Central Treatment Principle

Treatment should target:

The underlying disease, not the subretinal fluid alone.

There is no single medication or procedure appropriate for all exudative retinal detachments.

Treating Inflammatory Causes

For inflammatory disease such as:

• VKH
• Posterior scleritis
• Sympathetic ophthalmia

treatment may include:

• Systemic corticosteroids
• Steroid-sparing immunomodulatory therapy

depending on the specific disorder and severity.

Treating Posterior Scleritis

Posterior scleritis commonly responds to:

• Oral NSAIDs in mild cases
• Systemic corticosteroids in moderate or severe disease

Refractory disease may require immunomodulatory therapy.

Treating VKH

Acute VKH usually requires:

Prompt high-dose systemic corticosteroid therapy

often followed by:

• Slow taper
• Early steroid-sparing immunomodulatory treatment in selected patients

to reduce recurrence and chronicity.

Treating Hypertensive SRD

The priority is:

Urgent systemic blood-pressure control

rather than intraocular treatment.

This is especially important in:

• Malignant hypertension
• Preeclampsia/eclampsia

Treating Preeclampsia/Eclampsia-Related Detachment

Management focuses on:

• Obstetric stabilization
• Blood-pressure control
• Management of preeclampsia/eclampsia

The retinal detachment usually resolves spontaneously as the systemic condition improves.

Treating Central Serous Chorioretinopathy

Many acute CSC cases resolve spontaneously.

Management includes:

• Discontinuing or reducing corticosteroids when medically feasible
• Observation for acute uncomplicated cases

For chronic or recurrent active disease:

Reduced-fluence or reduced-dose photodynamic therapy with verteporfin is a major modern treatment option.

Why Conventional Laser Is Less Central in CSC

Focal thermal laser may still be used for selected extrafoveal focal leaks, but:

PDT is generally preferred for chronic central or diffuse disease

because conventional laser can cause:

• Scotoma
• Scar enlargement
• Secondary CNV

Treating Coats Disease

The definitive approach is closure of abnormal telangiectatic vessels using:

• Laser photocoagulation
• Cryotherapy when necessary

Anti-VEGF may be used as an adjunct in selected cases but:

Does not replace treatment of the abnormal vessels.

Treating Choroidal Hemangioma

Symptomatic circumscribed choroidal hemangioma with SRF may be treated with:

• Photodynamic therapy
• Plaque radiotherapy in selected cases
• Other radiation techniques for extensive disease

PDT is commonly preferred for accessible circumscribed lesions.

Treating Choroidal Melanoma

Management depends on:

• Tumor size
• Location
• Visual potential
• Metastatic risk

Options may include:

• Plaque brachytherapy
• Proton beam radiotherapy
• Enucleation in selected advanced cases

The SRF usually improves when the tumor is successfully treated.

Treating Optic Disc Pit Maculopathy

Options include:

• Observation in selected cases
• Pars plana vitrectomy
• Gas tamponade
• Induction of PVD
• Various adjunctive techniques

Laser temporal to the disc is now used more selectively.

Treating Uveal Effusion Syndrome

Management depends on etiology.

Nanophthalmic or scleral-thickening cases may require:

Scleral windows or partial-thickness sclerectomy

to improve transscleral fluid drainage.

Anti-VEGF Is Not a Universal SRD Treatment

A major modern correction is:

Intravitreal anti-VEGF should not be used simply because subretinal fluid is present.

It is appropriate only when the underlying mechanism is VEGF-driven, such as:

• CNV
• Some retinal vascular tumors
• Selected Coats disease adjunctively
• Neovascular complications

Steroids Are Also Cause-Specific

Likewise, corticosteroids may dramatically improve inflammatory SRD but can:

Worsen central serous chorioretinopathy.

Therefore therapy must be based on the correct diagnosis.

When Surgery Is Needed

Surgery is uncommon for purely exudative detachment itself.

It may be required for:

• Optic disc pit maculopathy
• Uveal effusion syndrome
• Advanced Coats disease
• Associated traction
• Tumor-related complications
• Persistent structural retinal problems

How Follow-Up Is Determined

Follow-up frequency depends entirely on the cause.

Monitor:

• Visual acuity
• OCT fluid
• Extent of detachment
• Choroidal findings
• Inflammation
• Underlying systemic disease

Some conditions require:

• Daily or urgent review

while others can be monitored over:

• Weeks to months

Expected Visual Outcome

Prognosis depends on:

• Cause
• Duration of detachment
• Foveal involvement
• Photoreceptor damage
• Underlying choroidal/RPE disease

Short-lived serous detachments can resolve with excellent recovery.

Chronic fluid may produce:

• RPE atrophy
• Photoreceptor loss
• Permanent reduction in vision

Pregnancy-Associated Prognosis

SRD from preeclampsia/eclampsia usually has:

A favorable ocular prognosis

with spontaneous resolution after systemic stabilization.

Persistent poor vision should prompt evaluation for:

• Macular ischemia
• RPE infarction
• Other hypertensive complications

Potential Sequelae

Possible complications include:

• Photoreceptor degeneration
• RPE atrophy
• Macular scarring
• Choroidal neovascularization
• Chronic cystic retinal change
• Secondary glaucoma in selected diseases
• Permanent visual loss

Rare end-stage inflammatory or neoplastic disease can lead to:

• Hypotony
• Phthisis bulbi

High-Yield Takeaways

• Serous/exudative retinal detachment is accumulation of subretinal fluid without a retinal break and without primary vitreoretinal traction.
• The major mechanisms are choroidal hyperpermeability, breakdown of the blood-retinal barrier, RPE pump dysfunction, inflammation, vascular leakage, and tumor-related exudation.
• Important causes include VKH, posterior scleritis, severe hypertension/preeclampsia, CSC, Coats disease, choroidal tumors, optic disc pit, and uveal effusion syndrome.
• The retina is typically smooth and dome-shaped, unlike the corrugated retina of an acute RRD.
• Shifting subretinal fluid supports an exudative mechanism but is not always present.
• Always perform a careful peripheral examination to exclude a retinal break.
• OCT is the key test for documenting and monitoring subretinal fluid.
• FA and ICGA help identify the underlying leakage pattern and choroidal disease.
• B-scan is especially useful when media are opaque, a tumor is suspected, or posterior scleritis is being considered.
• The classic ultrasound clue for posterior scleritis is the T-sign.
• There is no universal laboratory panel; investigations should be directed by the suspected cause.
• Always check blood pressure, particularly with bilateral SRD, pregnancy, renal disease, or hypertensive retinal findings.
• Treatment is directed at the underlying disease, not simply at the presence of subretinal fluid.
• Anti-VEGF is not a generic treatment for SRD and should be used only when the mechanism is appropriately VEGF-driven.
• Corticosteroids are useful for inflammatory diseases such as VKH and posterior scleritis but may worsen central serous chorioretinopathy.
• Chronic CSC is now commonly treated with verteporfin photodynamic therapy, rather than automatically using focal thermal laser.
• Preeclampsia/eclampsia-associated serous detachments usually resolve with systemic and obstetric treatment.
• Long-term visual prognosis depends mainly on the underlying cause, duration of foveal detachment, and degree of photoreceptor/RPE damage.

Ophthalmology – Scleritis

Core Definition

Scleritis is a deep inflammatory disorder of the sclera and adjacent episcleral tissues that can threaten vision and, in severe cases, the structural integrity of the globe.

Typical features include:

• Severe deep ocular pain
• Violaceous scleral redness
• Ocular tenderness
• Possible reduction in vision
• Frequent association with systemic autoimmune disease

Scleritis may be:

• Immune mediated
• Infectious
• Occasionally associated with prior surgery or trauma

Importantly, scleral necrosis occurs only in the more severe necrotizing forms.

Main Clinical Subtypes

Scleritis is broadly divided into:

• Anterior scleritis
• Posterior scleritis

Anterior disease is far more common.

Widespread Anterior Inflammation

Diffuse anterior scleritis is the most common subtype.

Typical findings include:

• Broad area of deep scleral injection
• Violaceous discoloration
• Marked tenderness
• Deep aching or boring pain

It is generally less destructive than necrotizing disease.

Localized Nodular Disease

Nodular anterior scleritis presents with:

• A focal elevated scleral nodule
• Marked tenderness
• Deep vascular congestion
• Severe pain

The nodule is:

Fixed to the sclera and does not move freely

which helps distinguish it from nodular episcleritis.

Destructive Inflammatory Scleritis

Necrotizing scleritis with inflammation is the most severe anterior form.

Features include:

• Extreme ocular pain
• Deep scleral inflammation
• Avascular areas
• Scleral thinning
• Progressive tissue necrosis
• Bluish appearance from increased scleral transparency

Underlying uveal tissue may become visible through severely thinned sclera.

This form should raise urgent concern for:

Systemic vasculitis, especially granulomatosis with polyangiitis.

Painless Necrotizing Disease

Scleromalacia perforans is a form of necrotizing scleritis with little or no visible inflammation.

Typical features include:

• Progressive scleral thinning
• Minimal redness
• Minimal or absent pain

It is classically associated with longstanding:

Rheumatoid arthritis

Despite the name, actual spontaneous perforation is uncommon unless disease is very advanced.

Inflammation Behind the Globe

Posterior scleritis affects the sclera posterior to the equator.

Possible manifestations include:

• Deep pain
• Pain with eye movement
• Reduced vision
• Proptosis
• Restricted motility
• Optic disc edema
• Choroidal folds
• Exudative retinal detachment
• Choroidal thickening

The anterior eye may appear nearly normal, so the diagnosis can be missed.

Typical Patient Profile

Scleritis is uncommon and occurs most often in:

• Adults
• Middle age
• Women more often than men

However, it can occur at any age.

Mechanism of Inflammation

In noninfectious disease, pathogenesis involves:

• Immune-complex injury
• T-cell activation
• Cytokine-mediated inflammation
• Scleral vascular inflammation

Severe disease may progress to:

Occlusive vasculitis and tissue necrosis.

Important Systemic Associations

A substantial proportion of patients have an associated systemic inflammatory disorder.

Important conditions include:

• Rheumatoid arthritis
• Granulomatosis with polyangiitis
• Relapsing polychondritis
• Systemic lupus erythematosus
• Spondyloarthritis
• Inflammatory bowel disease
• Sarcoidosis
• IgG4-related disease
• Other systemic vasculitides

Scleritis may occasionally be the:

First clue to previously undiagnosed systemic disease.

Rheumatoid-Associated Scleritis

RA is especially associated with:

• Necrotizing scleritis
• Scleromalacia perforans
• Peripheral ulcerative keratitis

Severe ocular disease in RA may reflect:

Systemic rheumatoid vasculitis.

ANCA-Associated Vasculitic Disease

Granulomatosis with polyangiitis (GPA) is particularly important.

Associated systemic features may include:

• Chronic sinus disease
• Pulmonary symptoms
• Hematuria
• Renal dysfunction

Necrotizing scleritis in this setting requires:

Urgent systemic evaluation and treatment.

Infectious Causes

Although most scleritis is noninfectious, infection must be considered.

Risk factors include:

• Prior ocular surgery
• Pterygium surgery
• Scleral buckle
• Trauma
• Foreign body
• Mitomycin C exposure
• Immunosuppression

Possible organisms include:

• Pseudomonas
• Staphylococcus
• Nocardia
• Mycobacteria
• Aspergillus and other fungi
• HSV
• VZV
• Tuberculosis
• Syphilis

Clues Suggesting Infection

Features that should raise suspicion include:

• Prior surgery or trauma
• Scleral ulceration
• Purulent discharge
• Multifocal scleral abscesses
• Necrosis
• Poor response to corticosteroids
• Worsening after immunosuppression

Infectious scleritis treated with steroids alone may deteriorate rapidly.

Characteristic Pain Pattern

The classic symptom is:

Deep, boring ocular pain

which may radiate to:

• Brow
• Forehead
• Temple
• Cheek
• Jaw

Pain may:

• Wake the patient from sleep
• Worsen with eye movement
• Be disproportionate to the visible redness

Other Symptoms

Patients may also complain of:

• Red eye
• Photophobia
• Tearing
• Blurred vision
• Globe tenderness

Posterior disease may present mainly with:

• Pain
• Reduced vision
• Diplopia

A Notable Exception

Absence of pain does not exclude severe disease.

Scleromalacia perforans may be nearly painless despite extensive scleral thinning.

Typical Appearance on Examination

The sclera often appears:

Deep red to violaceous

rather than bright red.

This reflects involvement of deeper:

• Episcleral vessels
• Scleral vascular plexus

What to Inspect at the Slit Lamp

Examine the sclera in all directions of gaze for:

• Deep injection
• Nodules
• Avascular patches
• Scleral thinning
• Necrosis
• Corneal involvement

Also assess:

• Anterior chamber
• IOP
• Lens
• Peripheral cornea

Why the Cornea Must Be Checked

Scleritis may coexist with:

Peripheral ulcerative keratitis

This combination is particularly concerning for systemic:

• Rheumatoid vasculitis
• ANCA-associated vasculitis

Corneal thinning substantially increases the urgency of treatment.

Associated Anterior Uveitis

Severe scleritis may produce:

• Anterior chamber cells
• Flare
• Posterior synechiae

This generally indicates more extensive ocular inflammation.

Using the Blanching Test

Topical phenylephrine can help distinguish episcleritis from scleritis.

Episcleritis

Superficial vessels usually:

Blanch substantially

Scleritis

Deep vascular congestion:

Persists despite phenylephrine

The test is supportive rather than absolutely diagnostic.

Separating Scleritis From Episcleritis

Scleritis

• Deep severe pain
• Violaceous hue
• Globe tenderness
• Reduced vision possible
• Deep vessels do not blanch
• Strong systemic disease association
• Potentially vision-threatening

Episcleritis

• Mild discomfort
• Bright-red superficial injection
• Vision usually normal
• Superficial vessels blanch
• Usually self-limited

Posterior Segment Assessment

A dilated fundus examination is important, especially when vision is reduced.

Look for:

• Choroidal folds
• Optic disc edema
• Exudative retinal detachment
• Vitritis
• Macular abnormalities

Most Useful Test for Posterior Disease

B-scan ultrasonography is a major diagnostic tool.

Possible findings include:

• Posterior scleral thickening
• Choroidal thickening
• Fluid in the posterior sub-Tenon space

Classic Ultrasound Clue

The characteristic:

T-sign

results from fluid surrounding the optic nerve in the posterior sub-Tenon space.

It supports the diagnosis of posterior scleritis, but:

Its absence does not exclude the disease.

OCT Findings in Posterior Scleritis

OCT may demonstrate:

• Subretinal fluid
• Choroidal folds
• Macular edema
• Increased choroidal thickness

Serial OCT can be useful for monitoring treatment response.

When Cross-Sectional Imaging Is Helpful

MRI or CT may be useful when:

• Posterior scleritis is uncertain
• Orbital disease is suspected
• A mass must be excluded
• Optic nerve involvement is present

MRI may show:

• Scleral thickening
• Enhancement
• Adjacent orbital inflammatory changes

Building the Systemic Work-Up

Laboratory testing should be:

Targeted to the history, phenotype, and severity

rather than identical in every patient.

Useful Baseline Studies

Depending on context, tests may include:

• CBC
• Renal function
• Liver function
• ESR
• CRP
• Urinalysis

These help detect systemic inflammation and occult renal disease.

Testing for ANCA-Associated Vasculitis

When vasculitis is suspected, consider:

• PR3-ANCA
• MPO-ANCA

Also check:

• Creatinine
• Urinalysis

because occult glomerulonephritis may be present.

Evaluating for Rheumatoid Disease

When clinically appropriate, consider:

• Rheumatoid factor
• Anti-CCP antibody

Anti-CCP is especially useful when RA is suspected.

Excluding Important Infections

Testing often includes, when appropriate:

• Syphilis serology
• Tuberculosis screening with IGRA or locally appropriate testing

Additional infectious tests depend on:

• Exposure history
• Surgery
• Travel
• Immunosuppression

Role of Chest Imaging

Chest imaging may be useful when considering:

• Sarcoidosis
• Tuberculosis
• GPA

Chest CT is more sensitive than plain radiography when suspicion remains high.

When Microbiologic Sampling Is Needed

Suspected infectious scleritis may require:

• Scraping
• Culture
• PCR
• Scleral biopsy

particularly with:

• Necrosis
• Abscess formation
• Postoperative disease
• Failure of empiric treatment

Disorders That Mimic Anterior Scleritis

Important alternatives include:

• Episcleritis
• Conjunctivitis
• Peripheral ulcerative keratitis
• Severe keratitis
• Anterior uveitis
• Acute angle-closure glaucoma

Disorders That Mimic Posterior Scleritis

Important alternatives include:

• Choroidal melanoma
• Vogt-Koyanagi-Harada disease
• Uveal effusion syndrome
• Central serous chorioretinopathy
• Choroidal detachment
• Orbital inflammatory disease
• Choroidal metastasis

Overall Treatment Principles

Management depends on:

• Infectious vs noninfectious etiology
• Anterior vs posterior disease
• Presence of necrosis
• Associated systemic disorder
• Severity and visual threat

The goal is:

Rapid suppression of scleral inflammation before irreversible tissue damage occurs.

First Step in Mild Noninfectious Disease

For mild-to-moderate diffuse or nodular anterior scleritis, treatment often begins with:

An oral NSAID

Examples include:

• Ibuprofen
• Naproxen
• Indomethacin

assuming no renal, gastrointestinal, cardiovascular, or other contraindication exists.

Escalating Beyond NSAIDs

Systemic corticosteroid is generally used when there is:

• Persistent severe pain
• Failure of NSAIDs
• Posterior scleritis
• Vision-threatening disease
• Necrotizing inflammation

Systemic Corticosteroid Therapy

Oral prednisone or equivalent may be used.

The dose is tailored to:

• Severity
• Body weight
• Systemic diagnosis

The taper should follow:

Clinical response rather than a fixed calendar schedule.

When Intravenous Steroid Is Considered

High-dose IV corticosteroid may be used for:

• Severe posterior scleritis
• Rapidly progressive necrotizing disease
• Sight-threatening inflammation

usually while systemic evaluation is underway.

Limits of Topical Steroid Therapy

Topical corticosteroids penetrate poorly into the sclera.

Therefore:

Topical steroid alone is usually inadequate for true scleritis.

They may still be useful for associated:

• Anterior uveitis
• Corneal inflammation

Local Steroid Injection

Modern practice is more nuanced than older teaching.

Subconjunctival/periocular corticosteroid may be considered in selected:

Noninfectious, nonnecrotizing anterior scleritis

but should generally be avoided in:

• Infectious disease
• Necrotizing disease
• Significant scleral thinning

When Long-Term Immunomodulation Is Needed

Steroid-sparing therapy should be considered when:

• Disease recurs
• Long-term steroid is required
• Steroid toxicity develops
• Necrotizing disease is present
• Systemic vasculitis exists

Common Steroid-Sparing Medications

Frequently used agents include:

• Methotrexate
• Mycophenolate mofetil
• Azathioprine

Choice depends on:

• Underlying systemic disease
• Comorbidities
• Severity
• Prior treatment response

Therapy for Severe Vasculitic Scleritis

Necrotizing disease associated with systemic vasculitis may require:

• Rituximab
• Cyclophosphamide

particularly in:

• GPA
• Severe systemic ANCA-associated disease

Management should be coordinated with:

• Rheumatology
• Internal medicine

Biologic Options for Refractory Disease

Biologic therapies may be used when conventional treatment fails.

Examples include:

• Infliximab
• Adalimumab
• Rituximab

Selection is guided by the underlying inflammatory disorder.

Treating an Infectious Cause

Infectious scleritis requires:

Organism-directed antimicrobial therapy

which may involve:

• Topical antibiotics
• Systemic antibiotics
• Antifungals
• Antivirals
• Surgical debridement

Steroid escalation should be avoided until infection has been adequately addressed.

Pseudomonas-Related Disease

Pseudomonas aeruginosa is a classic cause of aggressive infectious scleritis after:

• Pterygium surgery
• Scleral surgery
• Trauma

It may produce:

• Abscesses
• Necrosis
• Rapid scleral destruction

and often requires prolonged therapy.

Herpetic Scleritis

HSV and VZV may cause:

• Unilateral scleritis
• Keratitis
• Uveitis
• Reduced corneal sensation

A history of:

• Herpes zoster ophthalmicus
• Recurrent herpetic keratitis

may provide the clue.

Treatment generally includes:

Systemic antiviral therapy.

Protecting a Thinned Sclera

Patients with major scleral thinning should avoid:

• Eye rubbing
• Ocular trauma

Protective eyewear may be advisable when the structural integrity of the globe is compromised.

When Surgery Becomes Necessary

Surgery is rarely required but may be necessary for:

• Impending perforation
• Established perforation
• Severe scleral thinning
• Associated corneal melt

Reinforcing the Globe

A scleral or other tectonic patch graft may:

• Restore structural integrity
• Prevent perforation

However:

Surgery does not replace systemic control of active inflammation.

Signs That Treatment Is Working

Improvement is suggested by:

• Reduced pain
• Less tenderness
• Reduced vascular congestion
• Decreased scleral edema
• Stabilization of thinning
• Resolution of posterior fluid

Pain improvement is useful but cannot be relied upon alone, especially in:

Scleromalacia perforans.

Follow-Up Intensity

Review frequency depends on severity.

Severe, necrotizing, posterior, or infectious disease may require:

• Review within days
• Frequent reassessment during treatment changes

Stable cases can be followed less frequently.

Expected Disease Course

Recurrence is common.

Prognosis depends on:

• Scleritis subtype
• Presence of necrosis
• Posterior involvement
• Infectious etiology
• Associated systemic vasculitis
• Promptness of treatment

Diffuse and nodular anterior disease usually have:

Better visual outcomes than necrotizing disease.

Why Necrotizing Disease Is High Risk

Necrotizing scleritis is associated with:

• Severe ocular morbidity
• Systemic autoimmune vasculitis
• Risk of globe-threatening thinning

It should therefore be treated as both:

An ophthalmic and systemic urgency.

Possible Eye Complications

Important complications include:

• Scleral thinning
• Scleral perforation
• Peripheral ulcerative keratitis
• Anterior uveitis
• Cataract
• Secondary glaucoma
• Choroidal folds
• Exudative retinal detachment
• Macular edema
• Optic neuropathy
• Permanent visual loss

High-Yield Takeaways

• Scleritis is a deep, potentially sight-threatening inflammation of the sclera; necrosis is confined to the necrotizing subtypes.
• The principal forms are diffuse anterior, nodular anterior, necrotizing with inflammation, scleromalacia perforans, and posterior scleritis.
• The classic symptom is severe deep boring pain, often radiating to the brow or jaw and sometimes waking the patient from sleep.
• A violaceous hue, marked tenderness, and failure of deep vessels to blanch with phenylephrine favor scleritis over episcleritis.
• Scleromalacia perforans can be painless despite profound scleral thinning, especially in longstanding rheumatoid arthritis.
• Important systemic associations include rheumatoid arthritis, granulomatosis with polyangiitis, relapsing polychondritis, SLE, and other systemic vasculitides.
• Necrotizing disease should trigger urgent evaluation for ANCA-associated vasculitis.
• Always consider infectious scleritis before escalating immunosuppression, especially after surgery or trauma.
• Pseudomonas is a classic cause of severe postoperative infectious scleritis.
• Posterior scleritis may cause choroidal folds, optic disc edema, exudative retinal detachment, and painful visual loss.
• The classic B-scan finding is the T-sign, caused by fluid in the posterior sub-Tenon space.
• Mild noninfectious anterior disease may respond to oral NSAIDs.
• More severe, posterior, or refractory disease usually requires systemic corticosteroids.
• Chronic or recurrent disease often needs steroid-sparing immunomodulation, commonly methotrexate, mycophenolate, azathioprine, rituximab, or other agents tailored to the systemic disorder.
• Topical corticosteroid alone is usually inadequate for true scleritis.
• Local steroid injection may be considered only in carefully selected noninfectious, nonnecrotizing cases.
• Scleral patch grafting is reserved mainly for impending or actual perforation and must be combined with adequate control of the underlying inflammatory process.
• The major threats are scleral necrosis, perforation, peripheral ulcerative keratitis, glaucoma, posterior segment complications, and systemic vasculitis.

Ophthalmology – Schnyder’s Corneal Dystrophy

What the Disorder Represents

Schnyder corneal dystrophy (SCD) is a rare, bilateral, usually symmetric autosomal dominant stromal corneal dystrophy caused by abnormal deposition of lipids—particularly cholesterol and phospholipids—within the cornea.

Typical changes include:

• Central anterior stromal haze
• Crystalline deposits in some patients
• Progressive corneal arcus
• Increasing midperipheral stromal haze with age

An important modern point is:

Visible corneal crystals are not required for the diagnosis.

For this reason, the preferred name is Schnyder corneal dystrophy, rather than the older term “Schnyder crystalline corneal dystrophy.”

Who Tends to Be Affected

SCD is very uncommon and has been reported worldwide.

Features include:

• Often recognized in childhood or early adulthood
• Slowly progressive over decades
• Usually bilateral
• No strong sex predilection

A historically large pedigree was identified in individuals of:

Swede-Finn ancestry

but the disorder is not confined to this population.

How It Is Inherited

SCD follows an:

Autosomal dominant inheritance pattern

with variable expression.

An affected individual therefore typically has a:

50% chance of transmitting the pathogenic variant to each child

although clinical severity can differ considerably among relatives.

The Main Genetic Defect

SCD is caused by pathogenic variants in:

UBIAD1

located on:

Chromosome 1p36

UBIAD1 encodes a prenyltransferase involved in cellular lipid and cholesterol homeostasis.

Why Lipid Accumulates in the Cornea

Abnormal UBIAD1 function disrupts:

• Intracellular cholesterol handling
• Lipid metabolism
• Sterol trafficking

leading to accumulation of:

• Unesterified cholesterol
• Cholesterol esters
• Phospholipids

within:

• Bowman layer
• Anterior stroma
• Eventually deeper stromal tissue

Relationship to Blood Lipids

SCD is associated with increased frequency of:

• Hypercholesterolemia
• Hypertriglyceridemia

However:

Systemic dyslipidemia is not required for SCD to occur.

A patient can have genetically confirmed SCD with:

• Normal serum cholesterol
• Normal triglycerides

Thus the corneal disorder is primarily due to:

Intrinsic abnormal corneal lipid metabolism.

Other Systemic Associations

Reported associations include:

• Xanthelasma
• Hyperlipidemia
• Premature cardiovascular risk related to dyslipidemia
• Rare historical reports of genu valgum

These associations are not sufficiently specific to diagnose SCD.

How the Cornea Changes With Age

SCD often evolves in a characteristic age-related pattern.

Earlier Years

Patients may develop:

• Central stromal haze
• Fine crystalline deposits

Young to Middle Adulthood

A prominent:

Corneal arcus

may develop.

Later Adulthood

There may be progressive:

• Midperipheral stromal haze
• Generalized corneal clouding
• Loss of transparency

The exact timing varies substantially among families.

The Crystalline Variant

Some patients develop:

Fine, highly refractile polychromatic crystals

within the central anterior stroma.

They may appear:

• Needle-like
• Rectangular
• Plate-like

However, a substantial proportion of affected patients have:

No visible crystals at all.

SCD Without Crystals

The absence of crystals can make the diagnosis more difficult.

Noncrystalline SCD may present primarily with:

• Central haze
• Premature arcus
• Progressive stromal clouding

and can be mistaken for:

• Lipid keratopathy
• Other stromal dystrophies
• Metabolic corneal disease

Family history and genetic testing can be especially helpful in these cases.

Typical Symptoms

Patients may remain asymptomatic for years.

Symptoms can include:

• Glare
• Halos
• Photophobia
• Reduced contrast sensitivity
• Blurred vision

Glare often develops before substantial loss of Snellen visual acuity.

Why Bright Light Can Be Difficult

Deposited lipid and stromal haze scatter incoming light.

This can cause disproportionate visual difficulty under:

Photopic or glare conditions

even when standard visual acuity remains relatively good.

Effect on Visual Acuity

Central acuity is often preserved early.

Progressive visual loss usually results from:

• Increasing central stromal haze
• Broader stromal lipid deposition
• Light scatter

Severe disease can eventually cause:

Clinically significant corneal opacity.

Changes in Corneal Sensation

Corneal sensation may gradually become:

Reduced

over areas of stromal disease.

This is usually a late or progressive finding rather than an early diagnostic hallmark.

What the Slit Lamp Shows

Typical findings include:

• Bilateral central stromal haze
• Crystalline deposits in some patients
• Progressive corneal arcus
• Midperipheral stromal clouding with age

The epithelium is usually:

Relatively normal

because the primary pathology is stromal.

Where the Deposits Are Located

Deposits are typically concentrated in:

• Bowman layer
• Anterior stroma

With progression they can involve:

• Deeper stromal layers

The posterior cornea is relatively spared until advanced disease.

Microscopic Appearance

Histopathology can demonstrate:

• Lipid deposition in Bowman layer and stroma
• Cholesterol crystals
• Disruption of stromal organization

Special lipid stains such as:

Oil Red O

may demonstrate deposited neutral lipid in appropriately processed tissue.

Confocal Microscopy Findings

In vivo confocal microscopy may show:

• Needle-shaped crystals
• Rectangular refractile deposits
• Hyperreflective stromal material

It can support the diagnosis but is:

Not required in a typical case.

How the Diagnosis Is Established

Diagnosis is usually based on:

• Characteristic bilateral corneal appearance
• Family history
• Age-related progression
• Exclusion of systemic crystalline keratopathies

Genetic confirmation is available through:

UBIAD1 testing.

When Genetic Testing Is Most Helpful

Genetic testing is particularly useful when:

• Crystals are absent
• The phenotype is atypical
• Family counseling is needed
• A metabolic or hematologic mimic is being considered

A pathogenic UBIAD1 variant strongly supports the diagnosis.

What Blood Testing Is Worth Doing

Because dyslipidemia occurs relatively frequently, patients should generally have assessment of:

• Fasting or nonfasting lipid profile
• Total cholesterol
• LDL cholesterol
• HDL cholesterol
• Triglycerides

Abnormal results should be managed according to:

General cardiovascular-risk guidelines.

Important Modern Treatment Principle

Lowering serum cholesterol is important when dyslipidemia is present, but:

Lipid-lowering medication does not reliably remove existing corneal deposits or halt the inherited corneal dystrophy.

Statins or other agents should therefore be prescribed for:

• Cardiovascular indications
• Systemic lipid control

rather than as direct corneal therapy.

Disorders That Can Resemble SCD

Important alternatives include:

• Cystinosis
• LCAT deficiency
• Monoclonal gammopathy-associated crystalline keratopathy
• Multiple myeloma-associated corneal deposits
• Infectious crystalline keratopathy
• Gout-related crystalline deposits
• Tangier disease
• Other lipid keratopathies

Distinguishing It From Cystinosis

Schnyder Corneal Dystrophy

• Autosomal dominant
• UBIAD1-related
• Stromal cholesterol/lipid deposition
• Often central haze ± crystals
• Slowly progressive

Cystinosis

• Systemic lysosomal storage disorder
• Cystine crystals
• Dense crystals throughout cornea
• May have renal and systemic disease
• Photophobia often prominent

Distinguishing It From Infectious Crystalline Keratopathy

Infectious crystalline keratopathy typically shows:

• Branching stromal infiltrates
• Infectious context
• Often prior surgery, steroid use, or compromised cornea

SCD is:

• Bilateral
• Slowly progressive
• Noninflammatory
• Hereditary

Distinguishing It From Monoclonal Gammopathy

Crystalline corneal deposits associated with monoclonal gammopathy may signal:

• MGUS
• Multiple myeloma
• Other plasma-cell disorders

These patients may require:

• Serum protein electrophoresis
• Immunofixation
• Hematologic evaluation

when the corneal phenotype is atypical for inherited SCD.

Managing Mild Disease

Patients with good functional vision generally require:

Observation only.

Management may include:

• Updated spectacle correction
• Glare-reducing lenses
• Tinted lenses if helpful

No topical medication has been shown to eliminate the stromal lipid deposits.

Reducing Glare

Patients troubled primarily by glare may benefit from:

• Sunglasses
• Polarized lenses
• Selective tints

These improve symptoms but:

Do not alter disease progression.

When PTK Can Help

Phototherapeutic keratectomy (PTK) can be considered when visually significant deposits are:

• Superficial
• Confined mainly to the anterior cornea

PTK may improve:

• Corneal clarity
• Glare
• Visual acuity

Limitations of PTK

PTK cannot adequately treat:

• Deep stromal disease
• Extensive diffuse haze

It may also cause:

• Hyperopic refractive shift
• Corneal haze
• Recurrence of deposits

because the underlying genetic abnormality remains.

When Corneal Transplantation Is Needed

Advanced visually significant stromal opacity may require:

• Deep anterior lamellar keratoplasty (DALK)
• Penetrating keratoplasty in selected cases

Because the endothelium is generally healthy:

Lamellar transplantation is attractive when technically feasible.

Why DALK Can Be Advantageous

DALK preserves the patient’s own endothelium and therefore avoids:

• Endothelial rejection
• Some long-term endothelial graft complications

It is appropriate when disease is primarily:

Stromal.

When Penetrating Keratoplasty Is Considered

PK may be necessary when:

• Stromal disease is very deep
• Previous surgery has altered anatomy
• DALK is technically unsuitable

Visual prognosis after successful transplantation is generally good.

Recurrence After Surgery

SCD can recur after:

• PTK
• Lamellar grafting
• Penetrating keratoplasty

because recipient keratocytes and the underlying genetic defect remain capable of abnormal lipid handling.

Recurrence is typically:

Slow and may take many years.

Monitoring the Disease Over Time

Stable patients can generally be reviewed periodically, often:

Annually

rather than requiring a fixed 6-month schedule for every patient.

Monitor:

• Visual acuity
• Glare
• Corneal haze
• Crystalline deposition
• Arcus
• Corneal sensation

Closer follow-up is appropriate if:

• Visual function is changing
• Surgery is being considered

Family Evaluation

Because SCD is autosomal dominant, examination of:

• Parents
• Siblings
• Children

may reveal subtle or presymptomatic disease.

Genetic counseling can clarify:

• Transmission risk
• Testing options
• Variable expression

Expected Long-Term Course

The disease generally progresses:

Slowly over decades.

Many patients retain:

• Useful vision
• Good central acuity

for a long period.

A minority eventually develop enough stromal haze to require:

• PTK
• Keratoplasty

Factors Affecting Visual Function

Vision depends more on:

• Extent of stromal haze
• Central opacity
• Light scatter

than on the mere presence of visible crystals.

This explains why:

A patient with few or no crystals may still develop substantial visual impairment.

Potential Long-Term Problems

Possible complications include:

• Progressive stromal haze
• Glare disability
• Reduced contrast sensitivity
• Reduced corneal sensation
• Significant visual impairment
• Recurrence after PTK
• Recurrence within a corneal graft

Ophthalmology Pearls

• Schnyder corneal dystrophy is a rare autosomal dominant stromal dystrophy caused by pathogenic variants in UBIAD1 on chromosome 1p36.
• The fundamental abnormality is corneal cholesterol and phospholipid deposition.
• Crystals are not obligatory, which is why “Schnyder corneal dystrophy” is preferred over the older term “Schnyder crystalline corneal dystrophy.”
• Typical evolution includes central stromal haze ± crystals, premature corneal arcus, and increasing midperipheral stromal haze with age.
• Patients may complain of glare before measurable loss of standard visual acuity.
• Visible deposits are usually concentrated in Bowman layer and the anterior stroma.
• SCD may be associated with hypercholesterolemia and hypertriglyceridemia, but a normal lipid profile does not exclude the diagnosis.
• Obtain a lipid profile because systemic dyslipidemia should be treated for cardiovascular health.
• Lipid-lowering therapy does not reliably clear the corneal deposits and is not a direct treatment for SCD.
• Genetic testing for UBIAD1 is especially helpful in noncrystalline or atypical cases.
• Important mimics include cystinosis, monoclonal gammopathy-related crystalline keratopathy, LCAT deficiency, and infectious crystalline keratopathy.
• Mild disease is usually managed with observation and glare control.
• PTK is useful for selected superficial visually significant deposits.
• Advanced stromal haze may require DALK or penetrating keratoplasty.
• Because the underlying genetic abnormality persists, recurrence can occur after PTK or corneal transplantation, although it is usually slow.
• Visual prognosis is generally favorable, and many affected patients retain useful central vision for decades.

Ophthalmology – Sarcoidosis

What the Disease Is

Sarcoidosis is a multisystem inflammatory disorder characterized by formation of:

Noncaseating granulomas

in affected tissues.

The cause remains uncertain, but the disease likely reflects an abnormal immune response in genetically susceptible individuals after exposure to one or more environmental or infectious triggers.

Frequently involved organs include:

• Lungs
• Intrathoracic lymph nodes
• Skin
• Eyes
• Nervous system
• Heart

Ocular disease may occur:

• Before systemic sarcoidosis is recognized
• During established systemic disease
• Occasionally as the predominant manifestation

Why It Matters to Ophthalmologists

Sarcoidosis can affect nearly every ocular structure, including:

• Conjunctiva
• Lacrimal gland
• Orbit
• Anterior chamber
• Vitreous
• Retina
• Choroid
• Optic nerve

The most important ophthalmic manifestation is:

Uveitis

which may be:

• Anterior
• Intermediate
• Posterior
• Panuveitic

Untreated inflammation can cause permanent visual loss through:

• Cystoid macular edema
• Glaucoma
• Cataract
• Retinal/choroidal damage
• Optic neuropathy

Who Is More Likely to Be Affected

Sarcoidosis occurs worldwide, but incidence varies considerably according to:

• Ethnicity
• Geography
• Age
• Genetic background

It commonly presents in:

Young and middle-aged adults

although children and older adults can also be affected.

Certain populations, including people of African ancestry and some Northern European groups, have higher rates of systemic disease.

Hereditary Susceptibility

Sarcoidosis is not inherited in a simple Mendelian pattern.

However:

• Familial clustering occurs
• First-degree relatives have increased risk
• Several HLA associations have been identified

One important susceptibility locus is:

HLA-DRB1

Genetic background can also influence:

• Clinical phenotype
• Organ involvement
• Prognosis

How Granulomas Develop

The current model involves exaggerated cell-mediated immunity.

A proposed sequence is:

Antigen exposure → macrophage activation → CD4+ T-cell recruitment → cytokine release → granuloma formation

Important immune mediators include:

• Tumor necrosis factor-α
• Interferon-γ
• Interleukins

Granulomas are composed mainly of:

• Epithelioid histiocytes
• Multinucleated giant cells
• T lymphocytes

What the Biopsy Shows

The characteristic pathologic finding is:

Noncaseating epithelioid granulomatous inflammation

However, this is not uniquely diagnostic of sarcoidosis.

Similar granulomas can occur with:

• Tuberculosis
• Fungal infection
• Foreign-body reactions
• Other granulomatous inflammatory disorders

Therefore infection must be excluded when clinically appropriate.

Typical Systemic Symptoms

Patients may report:

• Cough
• Dyspnea
• Chest discomfort
• Fatigue
• Fever
• Weight loss
• Arthralgia
• Skin lesions

Some patients are:

Completely asymptomatic systemically

despite radiographic disease.

Classic Systemic Presentations

Löfgren Syndrome

An acute sarcoidosis phenotype characterized by combinations of:

• Bilateral hilar lymphadenopathy
• Erythema nodosum
• Ankle arthritis or periarthritis
• Fever

It generally carries a:

Favorable prognosis.

Heerfordt Syndrome

Also called:

Uveoparotid fever

Classically includes:

• Uveitis
• Parotid gland enlargement
• Facial nerve palsy
• Fever

Not every component must be present.

What Patients With Eye Disease Notice

Ocular symptoms may include:

• Blurred vision
• Photophobia
• Ocular pain
• Redness
• Floaters
• Reduced contrast
• Metamorphopsia

Orbital or neurologic involvement may cause:

• Diplopia
• Ptosis
• Proptosis
• Visual field defects

Some patients remain asymptomatic despite active ocular inflammation.

Typical Anterior Segment Pattern

Sarcoidosis classically produces:

Granulomatous anterior uveitis

Typical findings include:

• Mutton-fat keratic precipitates
• Anterior chamber cells and flare
• Iris nodules
• Posterior synechiae

Iris Nodules

Two classic types are:

Koeppe Nodules

Located at the:

Pupillary margin

Busacca Nodules

Located on the:

Anterior iris surface

Neither is specific for sarcoidosis.

Angle Involvement

Gonioscopy may reveal:

• Trabecular meshwork nodules
• Peripheral anterior synechiae
• Characteristic tent-shaped PAS

Angle involvement may contribute to:

Secondary glaucoma.

Intermediate Uveitis Features

Sarcoidosis may produce:

• Vitreous cells
• Vitreous haze
• Inferior snowballs

A classic description is:

“String of pearls” vitreous opacities

These findings reflect inflammatory aggregates within the vitreous.

Retinal Vascular Inflammation

One of the classic posterior findings is:

Retinal periphlebitis

usually affecting retinal veins.

The typical ophthalmoscopic appearance is described as:

“Candle-wax drippings”

representing segmental perivascular inflammatory exudation.

Retinal and Choroidal Lesions

Posterior involvement may include:

• Peripheral punched-out chorioretinal scars
• Active choroiditis
• Multifocal choroidal lesions
• Choroidal granulomas
• Retinal vascular leakage
• Retinal ischemia
• Neovascularization in advanced disease

Optic Nerve Involvement

Sarcoidosis may affect the optic nerve through:

• Optic disc granuloma
• Optic neuritis
• Perineuritis
• Infiltration
• Compression
• Raised intracranial pressure

Possible findings include:

• Disc swelling
• Disc nodules
• Reduced acuity
• Dyschromatopsia
• RAPD
• Visual field loss

Optic nerve involvement is potentially:

Vision-threatening and often requires systemic therapy.

Lacrimal Gland Disease

Sarcoidosis can infiltrate the lacrimal glands and cause:

• Painless enlargement
• Dry eye
• Palpable superotemporal mass

Lacrimal gland enlargement may be:

• Unilateral
• Bilateral

and may provide an accessible biopsy site.

Orbital Disease

Orbital sarcoidosis may involve:

• Lacrimal gland
• Extraocular muscles
• Orbital fat
• Optic nerve sheath
• Other orbital tissues

Possible symptoms include:

• Proptosis
• Diplopia
• Eyelid swelling
• Pain
• Restrictive motility

It can mimic:

• Thyroid eye disease
• Idiopathic orbital inflammation
• Lymphoma
• IgG4-related disease

How Ocular Sarcoidosis Is Diagnosed

Diagnosis is based on a combination of:

• Compatible ocular findings
• Systemic evidence
• Imaging
• Laboratory support
• Histologic confirmation when available
• Exclusion of important mimics

A biopsy-proven diagnosis remains the strongest confirmation.

Modern Diagnostic Framework

Current approaches, including updated International Workshop on Ocular Sarcoidosis (IWOS) concepts, categorize disease according to the strength of:

• Ocular signs
• Systemic investigations
• Biopsy evidence

The exact category depends on whether systemic tissue has been histologically confirmed.

Why Biopsy Is Important

Whenever feasible, biopsy should target the:

Safest accessible involved tissue

rather than the eye.

Potential sites include:

• Skin lesion
• Enlarged lymph node
• Conjunctival nodule
• Lacrimal gland
• Pulmonary or mediastinal lymph node

Pulmonary tissue is often obtained using:

Bronchoscopy with endobronchial ultrasound-guided biopsy

when thoracic lymphadenopathy is present.

Conjunctival Biopsy

If visible conjunctival nodules are present, biopsy may be attractive because it is:

• Relatively accessible
• Less invasive than pulmonary biopsy

Random conjunctival biopsy has a lower yield than biopsy of:

Clinically abnormal tissue.

Chest Imaging

Thoracic imaging is one of the most useful systemic investigations.

Possible findings include:

• Bilateral hilar lymphadenopathy
• Mediastinal lymphadenopathy
• Interstitial pulmonary infiltrates

Chest X-Ray vs Chest CT

Chest radiography may detect typical hilar adenopathy, but:

Chest CT is more sensitive

especially in patients with:

• Normal or equivocal chest X-ray
• High clinical suspicion
• Ocular disease without obvious systemic manifestations

Serum ACE

Serum:

Angiotensin-converting enzyme (ACE)

may be elevated in active sarcoidosis.

However:

• Sensitivity is limited
• Specificity is imperfect
• Normal ACE does not exclude sarcoidosis

Levels may also be influenced by:

• ACE inhibitor therapy
• Age
• Other granulomatous diseases

Therefore ACE should be viewed as:

Supportive rather than diagnostic.

Soluble IL-2 Receptor

Serum:

Soluble interleukin-2 receptor (sIL-2R)

is increasingly used as a biomarker of sarcoid immune activity.

In many settings it may have:

Greater diagnostic sensitivity than ACE

although availability varies.

Serum Lysozyme

Lysozyme may also be elevated.

It can provide supportive evidence but is:

Neither sufficiently sensitive nor specific to establish the diagnosis alone.

Calcium Abnormalities

Sarcoid granulomas can increase vitamin D activation and cause:

• Hypercalcemia
• Hypercalciuria

Therefore evaluation may include:

• Serum calcium
• Renal function

depending on the systemic context.

Tuberculosis Must Be Excluded

One of the most important diagnostic alternatives is:

Tuberculosis

particularly in regions where TB is common.

Evaluation may include:

• Interferon-γ release assay
• Tuberculin skin testing
• Chest imaging
• Microbiologic testing when indicated

A negative TB screening test does not absolutely exclude:

Active tuberculosis.

Syphilis Must Also Be Considered

Because ocular syphilis can mimic nearly any form of uveitis, testing commonly includes:

• Treponemal testing
• Nontreponemal testing

before committing a patient to prolonged immunosuppression.

Why the Old Anergy Test Is Less Useful

Historical teaching emphasized:

• PPD anergy
• “Anergy panels”

These are now much less important in routine diagnosis.

Modern evaluation favors:

• Targeted TB testing
• Imaging
• Biomarkers
• Tissue diagnosis

Role of FDG-PET

FDG-PET/CT can help identify occult active systemic sites when:

• Routine imaging is unrevealing
• Biopsy is needed
• Neurosarcoidosis or multisystem disease is suspected

It is not required for every patient.

Gallium Scanning Today

Gallium scanning historically demonstrated:

• Lacrimal uptake
• Parotid uptake
• Pulmonary inflammation

including the classic:

Panda sign

but it has largely been replaced by:

• CT
• MRI
• FDG-PET

in modern practice.

OCT in Ocular Sarcoidosis

Macular OCT is essential for detecting:

• Cystoid macular edema
• Epiretinal membrane
• Subretinal fluid
• Vitreomacular traction

CME is one of the most important treatable causes of visual loss.

Fluorescein Angiography

FA can demonstrate:

• Retinal vascular leakage
• Periphlebitis
• Disc leakage
• Capillary nonperfusion
• Macular leakage
• Neovascularization

Wide-field FA is especially useful for:

Peripheral retinal vasculitis.

Indocyanine Green Angiography

ICGA may reveal:

• Choroidal inflammatory lesions
• Hypofluorescent dark dots
• Choroidal granulomatous involvement

It is particularly useful when choroidal disease is suspected.

Fundus Autofluorescence

FAF can document:

• Active and inactive chorioretinal lesions
• RPE damage
• Areas of previous inflammation

It is supportive rather than diagnostic.

OCT Angiography

OCTA may demonstrate:

• Capillary dropout
• Choriocapillaris abnormalities
• Secondary choroidal neovascularization

but it does not show:

Vascular leakage

and therefore does not replace FA for vasculitis assessment.

Orbital and Neurologic Imaging

MRI brain/orbits with contrast is important when there is:

• Optic neuropathy
• Cranial nerve dysfunction
• Proptosis
• Orbital mass
• Suspected neurosarcoidosis

Fat-suppressed orbital sequences can help define:

• Optic nerve enhancement
• Lacrimal gland disease
• Orbital infiltration

Major Diagnostic Mimics

Important alternatives include:

• Tuberculosis
• Syphilis
• Toxoplasmosis
• Vogt-Koyanagi-Harada disease
• Birdshot chorioretinopathy
• Sympathetic ophthalmia
• Multiple sclerosis-associated uveitis
• Primary vitreoretinal lymphoma
• Behçet disease
• Other retinal vasculitides

Orbital Conditions That Can Resemble Sarcoid

These include:

• IgG4-related orbital disease
• Lymphoma
• Idiopathic orbital inflammation
• Granulomatosis with polyangiitis
• Thyroid eye disease
• Lacrimal gland neoplasm

Tissue biopsy becomes particularly important when the diagnosis is uncertain.

Overall Treatment Strategy

Treatment depends on:

• Site of ocular inflammation
• Severity
• Laterality
• Threat to vision
• Systemic involvement

The goal is to:

Suppress active inflammation before irreversible structural damage occurs.

Managing Anterior Uveitis

For isolated anterior uveitis, first-line treatment usually includes:

Topical corticosteroid

such as prednisolone acetate, with frequency adjusted to severity.

Preventing Synechiae and Relieving Pain

Cycloplegic/mydriatic drops are useful when significant anterior chamber inflammation is present.

Benefits include:

• Relieving ciliary spasm
• Reducing pain
• Preventing or breaking posterior synechiae

Local Steroid Therapy

Intermediate or posterior disease may sometimes be treated with:

• Periocular corticosteroid
• Intravitreal corticosteroid
• Sustained-release steroid implant

particularly when inflammation or CME is:

• Unilateral
• Asymmetric

Risks include:

• Cataract
• Elevated IOP
• Glaucoma

When Systemic Corticosteroids Are Needed

Systemic corticosteroids are appropriate for:

• Bilateral posterior uveitis
• Severe panuveitis
• Optic nerve involvement
• Orbital disease
• Neurosarcoidosis
• Vision-threatening inflammation

Treatment generally begins with:

Oral prednisone or equivalent

with dose and taper individualized to severity and systemic disease.

When Steroid-Sparing Treatment Is Appropriate

Long-term immunomodulatory therapy should be considered when:

• Inflammation recurs during steroid taper
• High steroid doses are required chronically
• Steroid toxicity develops
• Disease is severe or bilateral

Common Immunomodulatory Options

Frequently used agents include:

• Methotrexate
• Mycophenolate mofetil
• Azathioprine

Methotrexate is one of the most commonly used steroid-sparing agents in ocular sarcoidosis.

Biologic Therapy

For refractory disease, anti-TNF monoclonal antibodies may be used, especially:

• Adalimumab
• Infliximab

These can be effective for:

• Refractory uveitis
• Retinal vasculitis
• CME
• Neurosarcoidosis

Important Safety Step Before Anti-TNF Therapy

Before starting anti-TNF therapy, screen for:

• Tuberculosis
• Hepatitis B
• Other significant infection risks

because TNF blockade can reactivate latent infection.

Treating Sarcoid Macular Edema

Cystoid macular edema should primarily be treated by:

Controlling inflammation

Options include:

• Topical steroid in selected mild anterior-associated cases
• Periocular steroid
• Intravitreal steroid
• Systemic steroid
• Steroid-sparing immunomodulation

OCT is used to monitor response.

Treating Secondary Glaucoma

IOP elevation may result from:

• Trabecular inflammation
• Peripheral anterior synechiae
• Chronic corticosteroid exposure

Treatment may include:

• Topical aqueous suppressants
• Other glaucoma medication
• Laser or surgery when necessary

Both:

Inflammation and IOP must be controlled.

Cataract Management

Cataract may result from:

• Chronic uveitis
• Corticosteroid treatment

Cataract extraction is best performed when intraocular inflammation has been:

Well controlled before surgery

whenever clinically possible.

Perioperative anti-inflammatory therapy is often required.

Surgery for Glaucoma

Uncontrolled inflammatory glaucoma may require:

• Trabeculectomy
• Glaucoma drainage device
• Other glaucoma procedures

Success is improved when:

Uveitis is adequately suppressed.

Long-Term Surveillance

Follow-up depends on disease activity.

Monitor:

• Visual acuity
• Anterior chamber activity
• Vitreous inflammation
• IOP
• Macular OCT
• Retinal vascular activity
• Medication toxicity

Systemic follow-up may involve:

• Pulmonology
• Rheumatology
• Neurology
• Cardiology
• Dermatology

depending on organ involvement.

Cardiac Sarcoidosis

Although primarily outside ophthalmology, cardiac involvement is important because it may cause:

• Conduction abnormalities
• Ventricular arrhythmias
• Heart failure
• Sudden cardiac death

Symptoms such as:

• Syncope
• Palpitations
• Unexplained dyspnea

warrant systemic evaluation.

Neurosarcoidosis

Neurologic involvement may cause:

• Cranial neuropathies
• Optic neuropathy
• Meningitis
• Hypothalamic/pituitary disease
• Myelopathy

Facial nerve palsy is a classic manifestation.

Expected Visual Outcome

Many patients retain good vision when:

• Inflammation is recognized early
• CME is treated promptly
• Glaucoma is controlled

The major predictors of poor visual outcome include:

• Chronic cystoid macular edema
• Posterior segment inflammation
• Optic nerve disease
• Secondary glaucoma
• Macular structural damage

Problems That Can Develop Over Time

Important ocular complications include:

• Chronic or recurrent uveitis
• Cystoid macular edema
• Secondary glaucoma
• Posterior synechiae
• Cataract
• Epiretinal membrane
• Retinal ischemia
• Neovascularization
• Optic neuropathy
• Permanent visual loss

Ophthalmology Pearls

• Sarcoidosis is a multisystem granulomatous disorder characterized by noncaseating granulomas, but infection—especially tuberculosis—must be excluded before attributing granulomas to sarcoid.
• Ocular sarcoidosis may precede the diagnosis of systemic disease.
• The classic anterior segment pattern is granulomatous anterior uveitis with mutton-fat KPs, Koeppe/Busacca nodules, and posterior synechiae.
• Trabecular nodules and tent-shaped peripheral anterior synechiae are characteristic angle findings.
• Vitreous snowballs or “string-of-pearls” opacities suggest intermediate involvement.
• The classic retinal vascular sign is segmental periphlebitis with “candle-wax drippings.”
• Sarcoidosis can produce choroidal granulomas, optic disc granulomas, lacrimal gland enlargement, and orbital disease.
• Cystoid macular edema is one of the most important treatable causes of visual loss.
• Chest CT is more sensitive than plain chest radiography for detecting hilar and mediastinal lymphadenopathy.
• Serum ACE is supportive but neither sensitive nor specific enough to diagnose or exclude sarcoidosis.
• Soluble IL-2 receptor can be a useful modern systemic biomarker and may outperform ACE in some settings.
• Gallium scanning is largely historical; modern evaluation more often uses CT, MRI, and FDG-PET when indicated.
• Tissue biopsy showing compatible noncaseating granulomas remains the strongest confirmation, preferably from an accessible extraocular site.
• Before immunosuppression, important mimics such as tuberculosis and syphilis should be excluded.
• Topical corticosteroid plus cycloplegia is standard for significant anterior uveitis.
• Posterior, bilateral, optic nerve, orbital, or severe disease often requires systemic corticosteroid therapy.
• Chronic or recurrent disease commonly requires steroid-sparing therapy such as methotrexate, mycophenolate, or azathioprine.
• Adalimumab or infliximab can be effective for refractory ocular sarcoidosis, with infection screening before treatment.
• The classic syndromes to remember are Löfgren syndrome = hilar adenopathy + erythema nodosum + ankle arthropathy, and Heerfordt syndrome = uveitis + parotid enlargement + facial nerve palsy ± fever.
• Long-term vision is determined mainly by control of macular edema, posterior inflammation, glaucoma, and optic nerve disease.